10-K 1 ihealthcare10k.htm FORM 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

FOR THE FISCAL YEAR ENDED November 30, ~~2015~~2016

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

COMMISSION FILE NUMBER: 000-55378

~~Opulent Acquisition~~IHEALTHCARE, ~~Inc~~INC.,

(Exact name of registrant as specified in its charter)

	Delaware	47-3002847
	(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
	141 NE 3rd Avenue, Miami, FL	33132
	3901 NW 28th Street, 2nd Floor, Miami, FL	33142
	(Address of Principal Executive Offices)	(Zip Code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities to be registered under Section 12(b) of the Act: None

Securities to be registered under Section 12(g) of the Exchange Act:

Title of each class

Name of each exchange on which

registered

Common Stock, $.0001

N/A

-1-

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

[ ] Yes [X] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

[ ] Yes [X] No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

[X] Yes [ ] No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

[ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a small reporting company. See definition of large accelerated filer, accelerated filer and small reporting company in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[X ] Yes [ [X] No

~~At November~~As ~~30, 2015, the last business day~~ of ~~the~~March ~~Registrant’s~~14, ~~most recently completed fiscal year~~2017, the aggregate market value of the voting common stock held by non-affiliates of the Registrant (without admitting that any person whose shares are not ~~included~~ included in such calculation is an affiliate) was approximately $0.

~~At February~~As 18of March 14, ~~2016~~2017, there were 20 1,~~000~~077,000 shares of the Registrant’s common stock, par value $0.0001 per share, issued and outstanding.

-2-

Table of Contents

TABLE OF CONTENTS

~~Opulent~~IHEALTHCARE, ~~Acquisition~~INC., Inc.,

PART I		PAGE
Item 1	Business	41
Item 1A	Risk Factors	5
Item 1B	Unresolved Staff Comments	69
Item 2	Properties	69
Item 3	Legal Proceedings	69
Item 4	Mine Safety Disclosures	69
PART II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	69
Item 6	Selected Financial Data	710
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	710
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	710
Item 8	Financial Statements and Supplementary Data	F1-~~F10~~F8
Item 9	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	811
Item 9A	Controls and Procedures	811
Item 9B	Other Information	811
PART III
Item 10	Directors, Executive Officers and Corporate Governance	912
Item 11	Executive Compensation	1013
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	1014
Item 13	Certain Relationships and Related Transactions, and Director Independence	1114
Item 14	Principal Accounting Fees and Services	1114
PART IV
Item 15	Exhibits, Financial Statement Schedules	1215
	Signatures	1215

-3-

Table of Contents

PART I

Item 1. Business.

~~Opulent~~Corporate Acquisition, Inc. was incorporated in the State of Delaware on November 25, 2014. Since inception, the Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination and has made no efforts to identify a possible business combination. As a result, the Company has not conducted negotiations or entered into a letter of intent concerning any target business. The business purpose of the Company is to seek the acquisition of or merger with, an existing company. The Company selected November 30th as its fiscal year end.History

The Company, ~~based~~was onoriginally ~~proposed~~incorporated ~~business activities, is a “blank check” company. The U.S. Securities and Exchange Commission~~with (the ~~“SEC”)~~name ~~defines~~Opulent ~~those~~Acquisition, ~~companies as “any development stage company that is issuing a penny stock~~Inc., ~~within~~ under the ~~meaning~~laws of ~~Section 3 (a)(51) of~~ the ~~Securities~~State ~~Exchange Act~~ of ~~1934,~~Delaware ason ~~amended~~November ~~(the “Exchange Act”)~~25, ~~and~~2014 ~~that has no specific business plan or purpose, or has indicated that its business plan is to merge~~ with an ~~unidentified~~objective ~~company~~to ~~or companies.” Under SEC Rule 12b-2 under the Exchange Act~~acquire, ~~the Company also qualifies as a “shell company,” because~~ ~~it has no~~ or ~~nominal~~merge ~~assets (other than cash) and no or nominal operations. Many states have enacted statutes~~with, ~~rules~~an ~~and~~operating regulations limiting the sale of securities of “blank check” companies in their respective jurisdictions. Management does not intend to undertake any efforts to cause a market to develop in our securities, either debt or equity, until we have successfully concluded a business ~~combination~~. ~~The Company intends to comply with the periodic reporting requirements of the Exchange Act for so long as it is subject to those requirements.~~

~~The Company~~On ~~was~~January ~~organized as a vehicle to investigate and~~14, if2016 ~~such~~Mr. ~~investigation~~Jeffrey ~~warrants~~DeNunzio, ~~acquire a target company or business seeking~~ the ~~perceived~~sole ~~advantages~~shareholder of ~~being~~the aCompany, ~~publicly~~transferred ~~held~~to ~~corporation~~Ihealthcare, Inc., ~~The~~a Florida Company’s, ~~principal~~20,000,000 ~~business~~shares ~~objective~~of ~~for~~our ~~the~~common ~~next 12~~stock ~~months~~which ~~and~~represented ~~beyond~~all ~~such~~of ~~time~~our ~~will~~issued beand tooutstanding ~~achieve~~shares ~~long-term~~at ~~growth~~the ~~potential~~time ~~through~~of atransfer, ~~combination~~in ~~with~~consideration aof ~~business rather than immediate~~$25, ~~short-term earnings~~000. The ~~Company~~transfer was ~~will~~the ~~not~~result ~~restrict~~of ~~its~~the ~~potential~~sale ~~candidate~~of ~~target~~the ~~companies~~Company to ~~any specific business~~Ihealthcare, ~~industry or geographical location and~~Inc., ~~thus,~~the ~~may~~Florida ~~acquire any type of business~~Company.

~~-4-~~On January 14, 2016 Ihealthcare, Inc., a Florida Company, became the controlling shareholder of Opulent Acquisition, Inc. At the time of the sale of Opulent Acquisition, Inc., Mr. Mijares owned 62.5% and Mr. Bingaman owned 37.5% of the issued and outstanding shares of Ihealthcare, Inc., the Florida Company.

~~Table~~On January 14, 2016, Mr. Jeffrey DeNunzio ofresigned ~~Contents~~as Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director.

~~The analysis~~On ofJanuary ~~new~~14, ~~business~~2016, ~~opportunities~~Mr. ~~will be undertaken by or under the supervision of~~ Noel Mijares, ~~the~~was appointed ~~sole~~as ~~officer~~Chairman ~~and director~~ of the ~~Registrant.~~Board As of ~~this date~~Directors, ~~the~~Chief ~~Company~~Executive ~~has not entered into any definitive agreement with any party~~Officer, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for the Company. The Registrant has unrestricted flexibility in seeking, analyzing and ~~participating in potential business opportunities~~President. ~~In its efforts to analyze potential acquisition targets, the Registrant will consider the following kinds of factors:~~

~~(a)~~On ~~Potential~~January ~~for~~14, ~~growth~~2016, ~~indicated~~Mr. byDavid ~~new~~A. ~~technology,~~Bingaman was ~~anticipated~~appointed ~~market~~as ~~expansion~~Chief orOperating ~~new~~Officer, ~~products;~~Vice President, and Secretary.

On April 22, 2016 we, Opulent Acquisition, Inc. (b“Ihealthcare, Inc.-Delaware”) ~~Competitive~~entered ~~position~~into and consummated a merger with Ihealthcare, Inc., a Florida Company (“Ihealthcare, Inc.-Florida”). Ihealthcare, Inc.-Delaware is the Surviving Corporation as ~~compared~~result toof ~~other~~the ~~firms~~merger. The officers and directors of ~~similar~~Opulent ~~size~~Acquisition, Inc., now known as Ihealthcare, Inc., remained the same and ~~experience~~unchanged. ~~within~~Our officers and directors continue to serve their respective positions with the ~~industry~~Company. ~~segment~~Management astook ~~well~~a asview ~~within~~at the ~~industry~~acquisition asdate towards 805-50 and the eventual use of the rules covering a ~~whole;~~merger of entities under common control.

Previous to the Merger Noel Mijares owned 6,250 shares of common stock of Ihealthcare, Inc., the Florida Company and David A Bingaman owned 3,750 shares of common stock of Ihealthcare, Inc., the Florida Company. After the merger each one of these shares were converted into 100 shares of our common stock (cIhealthcare, Inc., a Delaware Company, formerly known as Opulent Acquistion, Inc). ~~Strength~~The ~~and~~20,000,000 ~~diversity~~shares of ~~management~~common stock owned by Ihealthcare, ~~either~~Inc., ina ~~place~~Florida orCompany ~~scheduled~~of ~~for~~Ihealthcare, ~~recruitment;~~Inc., formerly known as Opulent Acquistion Inc., a Delaware Company were cancelled upon consummation of the merger.

~~(d)~~Currently, ~~Capital~~Noel ~~requirements~~Mijares ~~and~~owns ~~anticipated~~625,000 ~~availability~~ shares of ~~required~~our ~~funds,~~common tostock beand ~~provided~~David byA ~~the~~Bingaman ~~Registrant~~owns ~~or from operations~~375,000 ~~through~~shares ~~the sale~~ of ~~additional~~our ~~securities,~~common ~~through joint ventures or similar arrangements or from other sources;~~stock.

~~(e)~~On ~~The~~April ~~cost~~22, of2016, ~~participation~~the byCompany filed with the ~~Registrant~~Delaware asSecretary ~~compared~~of State an amendment to the ~~perceived~~Company’s ~~tangible~~certificate ~~and~~of ~~intangible~~incorporation, ~~values~~changing ~~and~~its ~~potentials;~~name to Ihealthcare, Inc.

~~(f)~~On ~~The~~May ~~extent~~13, to2016 ~~which~~David ~~the~~A. ~~business~~Bingaman ~~opportunity~~was ~~can~~appointed as beChief ~~advanced;~~Financial Officer, Chief Accounting Officer, and Director.

~~(g)~~On July 25, 2016 we, Ihealthcare, Inc., organized Ihealthcare Surgical, LLC, a Florida Limited Liability Company. The ~~accessibility~~members of ~~required~~the ~~management~~LLC ~~expertise~~include Ihealthcare, ~~personnel~~Inc., ~~raw~~and ~~materials~~All in 1 Medical, ~~services~~LLC. Each of the aforementioned parties own 50% of the membership interests in Ihealthcare Surgical, ~~professional~~LLC. ~~assistance~~All ~~and~~in ~~other~~1 ~~required~~Medical, LLC ~~items;~~is owned and operated by Mark Heffner, who is a non-affiliate of Ihealthcare, Inc.

~~(h)~~As ~~Other~~of ~~relevant~~November ~~factors~~30, 2016 Ihealthcare Surgical, LLC has not had any monetary transactions. Per the above the Company has applied ASC 323 for presentation and disclosure requirements. Because Ihealthcare Surgical, LLC conducted no monetary business as of November 30, 2016 there were no transactions recorded on the books for the period.

~~Item~~On August 19, 2016 Ihealthcare 1ASurgical, LLC, entered into and consummated a joint venture agreement with All In 1 Medical, LLC. ~~Risk~~The ~~Factors~~purpose of the joint venture agreement is to forge a relationship that through means, which will be determined at a future date, will bring together both parties in an effort to sell, to be determined, medical products. Each party retains a 50% interest in the joint venture. Each party has also agreed to split profits and expenses equally that relate to the joint venture. The term of the joint venture agreement is through August 4, 2026. It may be renewed for an additional five year term if agreed upon by both parties. Each party of the joint venture agreement has agreed to contribute $500 for business purposes set forth in the joint venture agreement. Neither party has, as of the date of this report, contributed the $500, however both parties intend to make such contribution after a joint bank account is opened up for the purpose of the joint venture. Per the aforementioned ASC 808 does not apply since the entity, is setup as a wholly owned subsidiary and ASC 323 would not apply since there is no consideration paid as of November 30, 2016.

AsOn October 3, 2016 Ihealthcare Surgical, aLLC ~~smaller~~entered ~~reporting~~into ~~company~~and consummated an agreement with Precision Spine, Inc., “Precision,” to act as ~~defined~~Precision’s sales agent in ~~Rule~~regards ~~12b-2~~to the sale of spinal implants and other medical products that are manufactured for or by Precision. Ihealthcare, Inc. is to receive a 40% commission on the ~~Exchange~~sale ~~Act~~of spinal implants for the fourth quarter of 2016 and effective January of 2017, 35%, we+5% ~~are~~each ~~not~~quarter ~~required~~if Ihealthcare is able to ~~provide~~generate sales of $300,000 or more in a quarterly period. For “Biologic” products as they are categorized in the ~~information~~agreement, ~~called~~Ihealthcare will receive a to be decided upon commission that is agreed upon by both parties at a later date. Regarding disposable single use instruments, Ihealthcare, Inc. will receive a 20% commission for byany sales generated on Precision’s behalf. On December 6, 2016 iHealthcare Surgical, LLC and Precision Spine, Inc. mutually agreed to the termination of the agreement entered into on October 3, 2016. There were no revenues generated under this ~~Item~~agreement.

~~-5-~~ On October 10, 2016 our subsidiary, iHealthcare Surgical, LLC entered into an agreement with Gensano, LLC. Under the terms of the agreement iHealthcare Surgical, LLC will act as a sales agent for Gensano, LLC by attempting to sell products on their behalf. In this agreement iHealthcare Surgical, LLC will receive a sales commission which will be comprised of the difference between the price of Gensano’s products and the actual cost at which iHealthcare Surgical manages to sell the products. Gensano has set a fixed cost, per product, that they must receive from the sale of each item. IHealthcare Surgical, LLC will not directly purchase products from Gensano, and all shipping will be conducted directly from Gensano to the customer. There were no revenues generated under this agreement for the year November 30, 2016

~~Table~~On November 25, 2016 iHealthcare Surgical, LLC entered into an agreement with S1 Spine. Under the terms of ~~Contents~~the agreement S1 Spine has appointed iHealthcare Surgical, LLC to act as its sales agent to solicit orders for the products of S1 Spine. Sales are to be attempted, by iHealthcare Surgical LLC in Florida, Georgia, Nevada and New Mexico. In exchange for operating as the sales agent for S1 Spine, iHealtcahre Surgical shall receive a commission based upon the net invoice price of products offered for sale. There were no revenues generated under this agreement for the year November 30, 2016

~~Item~~On 1BFebruary 23, 2017 Ihealthcare, Inc. ~~Unresolved~~entered ~~Staff~~into ~~Comments~~an agreement with John Cook and Paul Pereira. Under the terms of the agreement John Cook and Paul Pereira will act as part time consultants for Ihealthcare, Inc. Their role shall pertain to assisting the Company with obtaining and structuring institutional financing from various commercial banks, investment banking firms, private equity firms and related financial and business issues. John Cook and Paul Pereira shall be compensated for their part time assistance as consultants through a combination of cash and stock incentives. John Cook and Paul Pereira shall be awarded a total of 10.00%, respectively, of Series B Preferred stock based upon acquisition milestones. The 10.00% to that point shall be Series B Preferred Stock, however, if they assist the Company in achieving gross revenues exceeding $200,000,000 then they will each be awarded an extra 2.5% of the Preferred Stock in a new class with the same rights as Series B. This would bring their total equity interest to 12.50% each, and 25.00% total.

~~None~~Our principal executive offices are located at 3901 NW 28th Street, 2nd Floor, Miami, FL 33142.

~~Item 2. Properties.~~-1-

~~We neither~~Table ~~rent nor own any properties. We utilize the home office space and equipment~~ of our management at no cost. Management estimates such amounts to be immaterial. We currently have no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.Contents

~~Item 3.~~Industry ~~Legal Proceedings.~~Overview

~~From time~~Drug toScreening time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future.Industry

~~Item~~The drug screening market-size is expected to grow from $4 billion in 2014 to $6.3 ~~Mine~~billion ~~Safety~~by ~~Disclosures~~2019, at a CAGR (Compound Annual Growth Rate) of 9.5%. Major factors driving the growth of this market include higher usage of alcohol, prescribed drugs, illicit drugs, and a growing aging population that leads to increased use of alcohol and prescription drugs. Funding by the U.S. Federal Governments for drug testing, enactment of stringent laws in developed countries, and growing awareness for drug testing in developing nations, has increased the awareness surrounding testing patients on a regular basis. In addition, emerging economies such as India, China, and Brazil present an array of opportunities for this market.

~~Not~~Currently, North America dominates the drug screening ~~applicable~~market, with the U.S. accounting for a major market share. However, the Asia-Pacific region is poised to grow at the highest CAGR during the forecast period. We believe there to be great growth potential in the Asian market due to development of advanced drug and alcohol screening devices in Japan, rising awareness regarding the importance of drug and alcohol screening, and increasing disposable income levels in various countries in Asia.

~~PART~~The North American laboratory, as well as onsite IItesting market, has increased by more than 5.0% CAGR between 2011 and 2014. With past technologies it was necessary to retest a positive lab test, due to potential inaccuracies, which resulted in a higher cost. New technology enables employers to retest positive results inexpensively, and immediately, with the same, and new, samples from the subject, thus reducing the overall cost.

~~Item 5.~~Business ~~Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.~~Information

~~Market~~We, Ihealthcare, Inc. are a Company that sells and distribute ~~Information~~products in the healthcare sector. We currently hold a distribution agreement with Innovate Laboratory Solutions, also known as “ILS” to supply us a product known as the “UDT Cup” (also herein known as Multi-Panel [16] urinalysis cup or Drug of Abuse “DOA” Cup). ILS has agreed to provide us the right to purchase the UDT Cup at special pricing in certain quantities. ILS is the developer of the UDT Cup and exclusive global supplier of the UDT Cup, however they have the UDT Cup manufactured by a third party manufacturer of which they have not and will not disclose to us due to confidentiality. ILS does however, have the authority and right to control who manufactures the UDT Cup.

~~ADMISSION~~We entered into and consummated the above agreement with TOILS ~~QUOTATION~~to ONsell ~~THE~~us ~~OTC~~the ~~MARKETPLACE~~UDT Cup at certain price points beginning on February 18, 2016. The term of the agreement is for a span of three years. We may buy the UDT Cup in varying quantities from ILS, provided they have enough inventory to fill our order, otherwise we will be limited to whatever they may have available at that time of order.

~~We intend to have our common stock be quoted on the OTC MarketPlace.~~ If ~~our~~both ~~securities~~parties ~~are~~in ~~not~~writing ~~quoted~~agree onto ~~the OTC MarketPlace, a security holder may find~~ it ~~more~~they ~~difficult~~can toterminate the ~~dispose~~above ~~of,~~mentioned oragreement. toOur ~~obtain~~agreement ~~accurate~~with ~~quotations~~ILS asalso tohas ~~the~~a ~~market~~section ~~value~~titled of“Termination ~~our~~for ~~securities~~Cause. ~~The~~” ~~OTC~~This ~~MarketPlace~~section states ~~differs from national and regional stock exchanges in~~ that it:

~~(1) is~~“a. ~~not~~Either ~~situated~~party inwill ahave ~~single~~the ~~location~~right ~~but~~to ~~operates~~terminate ~~through~~the Agreement ~~communication~~at ofany ~~bids,~~time ~~offers~~if ~~and~~the ~~confirmations~~other ~~between~~party ~~broker-dealers~~is in breach of any material term, and ~~(2)~~which ~~securities~~such ~~admitted~~party fails to ~~quotation~~cure ~~are~~within ~~offered~~10 bycalendar day ~~one~~after orreceiving ~~more~~written ~~Broker-dealers~~notice ~~rather~~of ~~than~~the breach and the ~~“specialist”~~party’s ~~common~~ intention to ~~stock exchanges~~terminate.

To qualify for quotation on the OTC MarketPlace, an equity security must have one registered broker-dealer, known as the market maker, willing to list bid or sale quotations and to sponsor the company listingb. WeILS doshall ~~not yet~~ have ~~an agreement with a registered broker-dealer, as~~ the ~~market~~right ~~maker, willing~~ to ~~list~~terminate ~~bid~~this orAgreement sale quotations and to sponsor the Company listing. If the Company meets the qualifications for trading securities on the OTC MarketPlace our securities will trade on the OTC MarketPlace until a future time, if ~~at all. We may not now and it may never qualify for quotation on the OTC MarketPlace.~~ Distributor:

~~Holders~~1. becomes insolvent;

~~As of~~2. ~~February~~discontinues ~~18,~~its ~~2016,~~business; ~~there was approximately one shareholder of record of our common stock and 20,000,000 shares of common stock deemed outstanding.~~or

~~Dividends~~3. becomes the subject of any voluntary or involuntary proceeding ~~and~~in ~~Share~~bankruptcy, ~~Repurchases~~liquidation, dissolution, receivership, attachment or composition for the benefit of creditors. Such termination will become effective upon the non-terminating party’s receipt of a notice of termination at any time after the specified event.

~~We have~~Such ~~not~~termination ~~paid~~will ~~any~~become ~~dividends~~effective toupon ~~our~~the ~~shareholder.~~non-terminating party’s ~~There~~receipt ~~are~~of noa ~~restrictions~~notice ~~which~~of ~~would~~termination ~~limit~~at ~~our~~any ~~ability~~time toafter ~~pay dividends on common equity or that are likely to do so in~~ the ~~future~~specified event.”

~~Issuer~~Per our agreement with ILS there are no specific laws ~~Purchases~~which we have expressly agreed to abide by. However, in general we have agreed to comply with all Federal and State healthcare laws, rules and regulations, including, but not limited to, Stark, Anti-Kickback, False Claims Act, etc. Non-compliance of ~~Equity~~any rule, ~~Securities~~regulation or law, including the aforementioned, could in some way cause us to become the party of a civil or criminal suit. Generally speaking when one is a party in any civil or criminal suit it may negatively affect that party’s image and may also cause them financial harm. If this were to happen to us we may have to curtail operations, or allocate funds towards defending ourselves in any such case. If we were found guilty of violating any rule, regulation, or law our operations may be terminated, suspended, or harmed in some capacity.

~~None~~The UDT Cup’s intended purpose is for drug screening.

~~Equity~~For the twelve months ended November 30, 2016 the Company ~~Compensation~~has ~~Plan~~generated ~~Information~~revenue in the amount of $1,428. The revenue was the result of sales of the “UDT Drug Screening Cup”.

~~Not applicable.~~Mission and Vision:

~~Recent~~At Ihealthcare, Inc. we are dedicated to reducing costs and ~~Sales~~improving the quality of ~~Unregistered~~medical ~~Securities;~~care ~~Uses~~through ofinnovative ~~Proceeds~~products and services in specialized markets that are currently being underserved by our competition. Our primary focus is to establish sustainable market penetration, one product at a time. Simultaneously, we seek to continue our current efforts to add additional products and/or services to our Company. When these new products and services are available we hope to have already acquired a dedicated customer base who can also benefit from ~~Registered~~our ~~Securities~~future products and services. At present, we have identified a number of complementary products and services which we will begin exploring as methods to support our plans to increase revenue and profitability.

~~Not applicable.~~Current Product(s):

Ihealthcare, Inc. has acquired the distribution rights and special pricing to the ILS “UDT Cup” Multi-6-Panel [16] urinalysis cup through our supplier Innovative Laboratory Solutions. The UDT Cup has been specifically designed to meet the latest market needs, needs which have been overlooked by the competition, at substantially lower costs.

~~Table of~~The ~~Contents~~UDT Cup has the following features:

~~Item 6.~~· ~~Selected~~Tests ~~Financial~~16 ~~Data.~~configurable panels simultaneously;

~~Not applicable~~· ~~because~~The ~~the~~configuration ~~Company~~can isbe acustomized ~~smaller~~to ~~reporting~~suit ~~company.~~customers’ testing needs;

~~Item 7.~~· ~~Management’s~~99% ~~Discussion and Analysis of Financial Condition and Results of Operations.~~accuracy;

~~The following~~· ~~discussion~~One ofstep ~~our~~lateral ~~financial~~flow condition and results of operations should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended November 30, 2015, found in this report. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as “anticipate,” “believe,” “intends,” or similar expressions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under “Risk Factors” in Part I, Item 1A of this report.process;

~~Company Overview~~ · Round or Square form factor – ease of scanning results;

~~Opulent~~· ~~Acquisition,~~Wider ~~Inc.~~test ~~(the~~strips ~~“Company”)~~for ~~was~~ease ~~incorporated~~in ~~under~~reading ~~the laws of the State of Delaware on November 25, 2014, with an objective to acquire, or merge with, an operating business.~~results;

~~Recent Developments:~~· Tight cap seal which serves to reduce erroneous results due to leakage;

~~None.~~· Test strip seal prevents cross contamination during inversion;

~~Critical Accounting~~· ~~Policies~~Design prevents over filling;

~~We prepare~~· ~~our~~Contains ~~financial~~more ~~statements~~urine involume ~~conformity~~for ~~with~~repeat ~~GAAP,~~tests ~~which~~as requires management to make certain estimates and assumptions and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the financial statements are prepared and actual results could differ from our estimates and such differences could be material. We have identified below the critical accounting policies which are assumptions made by management about matters that are highly uncertain and that are of critical importance in the presentation of our financial position, results of operations and cash flows. On a regular basis, we review our accounting policies and how they are applied and disclosed in our financial statements.needed;

~~Use of~~· ~~Estimates~~Results produced in one minute;

~~The preparation~~· ofBuilt ~~financial statements~~ in ~~conformity~~temperature with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Estimates are based on historical experience, management expectations for future performance, and other assumptions as appropriate. Key areas affected by estimates include the assessment of the recoverability of long-lived assets, which is based on such factors as estimated future cash flows. We re-evaluate estimates on an ongoing basisstrip; ~~therefore, actual results may vary from those estimates.~~

~~Fair Values~~· ofFemale ~~Financial~~user ~~Instruments~~friendly; and

~~The carrying~~· ~~values~~Integrated ofAdulteration ~~cash,~~Parameters ~~accounts~~with ~~receivable,~~visual ~~accounts~~integrity ~~payable~~check ~~and accrued expenses approximate the fair values of these instruments due to their short-term nature. The carrying amount~~ for: ~~borrowings~~pH, ~~under~~specific ~~the~~gravity, ~~financing~~creatinine, ~~agreement~~nitrite, ~~approximates~~oxidant, ~~fair~~blutaraldyhyde, ~~value~~bleach ~~because of~~and ~~the~~pyridinium ~~variable market interest rates charged for these borrowings~~chlorchromate.

~~Off Balance~~· ~~Sheet~~FDA ~~Arrangements~~510 Cleared

~~There are~~· noCLIA ~~off balance sheet arrangements.~~Waived

~~Capital Resources.~~-2-

~~We had~~Table ~~no material commitments for capital expenditures as~~ of ~~November 30, 2015 and 2014.~~Contents

~~Results~~Lateral ofFlow ~~Operations~~Process ~~for~~Expanded ~~the year ended November 30, 2015 and period from November 25, 2014 (inception) to November 30, 2014~~Definition

~~For~~Lateral ~~the~~flow ~~year~~tests also ~~ended~~known ~~November~~as lateral 30flow immunochromatographic assays, are ~~2015~~simple ~~and~~devices intended to detect the ~~period~~presence ~~from~~(or ~~inception~~absence) of a target analyte in sample (matrix) without the need for specialized toand ~~November~~costly 30equipment Typically, ~~2014,~~these wetests ~~did~~are ~~not~~used ~~generate~~for ~~any~~medical ~~revenues.~~diagnostics ~~For~~either ~~both~~for ~~periods~~home wetesting, point ~~also~~of ~~did~~care testing, or ~~not~~laboratory ~~have~~use. ~~any~~In ~~cash~~this orcase, ~~cash~~drugs ~~equivalents~~of abuse testing.

~~For~~The ~~the~~technology ~~year~~is ~~ended~~based ~~November~~on ~~30,~~a ~~2015~~series weof ~~had~~capillary ~~total~~beds, ~~general~~such as ~~and~~pieces ~~administrative expenses~~of inporous ~~the~~paper, microstructured ~~amount~~polymer, or sintered polymer. Each of ~~$7,496~~these ~~compared~~elements has the capacity to ~~total~~transport ~~general~~fluid &(e.g., ~~administrative~~urine) ~~expenses~~spontaneously. ofThe ~~$4,148~~first ~~for~~element (the ~~period~~sample ~~from~~pad) ~~inception~~acts as a sponge and holds an excess of sample tofluid. ~~November~~Once 30soaked, ~~2014.~~the ~~Our~~fluid ~~general~~migrates ~~and~~to ~~administrative~~the ~~expenses~~second ~~made~~element up(conjugate pad) in which the ~~entirety~~manufacturer ofhas ~~our~~stored ~~net~~the ~~loss~~so-called conjugate, ~~for~~a ~~both~~dried ~~periods~~format ~~respectively. The~~of ~~variance~~bio-active particles (see below) in ~~net~~a ~~loss~~salt-sugar ismatrix ~~due~~that contains everything to ~~increased~~guarantee ~~expenses~~an ~~for~~optimized chemical reaction between the ~~year~~target ~~ended~~molecule ~~November~~(e.g., 30an antigen) and its chemical partner (e.g., ~~2015~~antibody) that has been immobilized on the particle's surface.

~~Item~~While the sample fluid dissolves the salt-sugar matrix, it 7Aalso dissolves the particles and in one combined transport action the sample and conjugate mix while flowing through the porous structure. ~~Quantitative~~In this way, the analyte binds to the particles while migrating further through the third capillary bed. This material has one or more areas (often called stripes) where a third molecule has been immobilized by the manufacturer. By the time the sample-conjugate mix reaches these strips, analyte has been bound on the particle and ~~Qualitative~~the ~~Disclosures~~third ~~about~~'capture' ~~Market~~molecule ~~Risk~~binds the complex. After a while, when more and more fluid has passed the stripes, particles accumulate and the stripe-area changes color.

AsTypically there are at least two stripes: one (the control) that captures any particle and thereby shows that reaction conditions and technology worked fine, the second contains a ~~“smaller~~specific capture ~~reporting~~molecule ~~company”~~and only captures those particles onto which an analyte molecule has been immobilized. After passing these reaction zones the fluid enters the final porous material, wethe ~~are~~wick, ~~not~~that ~~required~~simply toacts ~~provide~~as a waste container. Lateral flow then means the combination ~~information~~of ~~required~~these byproprietary ~~this~~processes ~~Item~~that scientifically allow/create the draw or flow of the sample laterally across these membranes for analysis.

~~-7-~~*Sample diagrams of a generic lateral flow process for illustration only.

~~Table of~~Additional ~~Contents~~Feature Definitions

~~Item~~FDA Cleared: Cleared medical 8devices: These medical devices are ones that the FDA has determined to be substantially equivalent to another legally marketed device. ~~Financial~~A ~~Statements~~pre-market ~~and~~notification, ~~Supplementary~~referred ~~Data~~to as a 510(k), must be submitted to FDA for clearance. A 510(k) is most often submitted by the medical device manufacturer.

~~Opulent~~CLIA ~~Acquisition~~Waived: Testing on human specimens for health assessment or the diagnosis, ~~Inc~~prevention, or treatment of disease are regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). As defined by CLIA, waived tests are simple tests with a low risk for an incorrect result. They include certain tests listed in the CLIA regulations, tests cleared by the FDA for home use, and tests approved for waiver by the FDA using the CLIA criteria.

~~FINANCIAL~~The ~~STATEMENTS~~UDT Cup boasts 16 Drug Screening Panels which include: Amphetamines AMP; Barbiturates BAR; Buprenorphine BUP; Benzodiazepines BZO; Cocaine COC; Methamphetamines [2] mAMP & MDMA; Methadone MTD; Opiates OPI; Oxycodone OXY; Phencyclidine PCP; Marijuana THC; and Tricyclic Antidepressants TCA. Tests for Morphine MOR; Ketamine KET and Propoxyphene PPX or others can be added. Pregnancy tests also available.

~~INDEX TO FINANCIAL STATEMENTS~~Shipping

		Pages
Report of Independent Registered Public Accounting Firm		F2
Balance Sheets		F3
Statements of Operations		F4
Statements of Changes in Stockholders’ Deficit		F5
Statements of Cash Flows		F6
Notes to Financial Statements		F7-F10

ILS is solely responsible for the shipment of all UDT Cups, with their primary shipping location based in Miami, Florida. Shipping is paid for solely by the consumer and if there are any problems or damage resulting from the shipment of UDT Cups then the liability for replacement products will fall on ILS. In the event that a product is damaged Ihealthcare, Inc. will notify ILS and return the shipment back to the Miami warehouse, whereupon it will be replaced and re-shipped to the consumer at no additional shipping cost to the customer.

~~-F1-~~The UDT cup that we currently sell may be purchased by any individual.

~~Table of~~Uses ~~Contents~~and other information regarding the UDT Cup:

~~REPORT~~The UDT Cup is intended for detecting the presence of drugs OFin ~~INDEPENDENT~~urine. ~~REGISTERED~~Any ~~PUBLIC~~situation ~~ACCOUNTING~~it ~~FIRM~~may be necessary to screen an individual for drug use would be an appropriate time to utilize the UDT Cup. Examples include but are not limited to screening potential employees, current employees, use in drug treatment centers or medical clinics.

ToPotential purchasers of the UDT Cup can be anyone however, most notably we anticipate it will be primarily medical clinics, hospitals, drug rehabilitation centers, Employers, Physician groups, transportation companies (used to test drivers for drug use) or wholesalers who will resell the ~~Board~~product ofat ~~Directors~~a ~~and~~higher ~~Stockholder~~cost to make a profit. We have no intentions of limiting who can buy the UDT Cup.

~~Opulent Acquisitions~~The UDT cup is comprised of two elements, ~~Inc~~the test cup and dipcard.

~~Miami~~Rapid Single/Multi-drug test Cup and Rapid Single/Multi-drug test Dipcard are lateral flow chromatographic immunoassays designed to qualitatively detect the presence of drugs and drug metabolites in human urine and are classified under the following product code, classification, regulatory section and panel; ~~Florida~~ Product Code; Classification; Regulatory Section; Panel DKZ Class II 862.3100 Amphetamine test system Toxicology (91) DJC Class II 862.3610 Methamphetamine test system Toxicology (91) DIO Class II 21 CFR 862.3250 Cocaine test system Toxicology (91) DNK Class II 21 CFR 862.3640 Morphine test system Toxicology (91) LDJ Class II 21 CFR 3870 Cannabinoid test system Toxicology (91) DIS Class II 21 CFR 862.3150 Barbiturate test system Toxicology (91) JXM Class II 21 CFR 862.3170 Benzodiazepine test system Toxicology (91) DJR Class II 21 CFR 862.3620 Methadone test system Toxicology (91) DJG Class II 21 CFR 862.3650 Opiate test system Toxicology (91) LCM Unclassified Enzyme immunoassay, Phencyclidine test system Toxicology (91)

~~We have~~The ~~audited~~class ~~the~~to ~~accompanying~~which your ~~balance~~device ~~sheets~~is ofassigned ~~Opulent~~determines ~~Acquisitions, Inc. (~~the ~~"Company")~~type as of ~~November~~premarketing ~~30,~~submission/application ~~2015~~required ~~and 2014~~for ~~and~~FDA ~~the~~clearance ~~related~~to ~~statements~~market. ofIf ~~operations,~~your device ~~changes~~is inclassified ~~stockholders’~~as ~~deficit~~Class ~~and~~I ~~cash~~or ~~flows for the year ended November 30~~II, ~~2015~~ and ~~for~~if ~~the~~it ~~period~~is ~~from~~not ~~November 25~~exempt, ~~2014~~a ~~(inception)~~510k ~~November~~will ~~30,~~be ~~2014.~~required ~~These~~for ~~financial statements are the responsibility of the Company's management~~marketing. ~~Our responsibility is to express an opinion on these financial statements based on our audits.~~

WeA ~~conducted~~company ~~our~~that ~~audits~~intends to market in ~~accordance~~the US a Class I, ~~with~~II, ~~standards~~or ofIII ~~the~~medical ~~Public~~device ~~Company~~intended ~~Accounting~~for ~~Oversight~~human ~~Board~~use, ~~(United~~for ~~States~~which a Premarket Approval (PMA). ~~Those~~is ~~standards~~not ~~require~~required, ~~that~~must wesubmit ~~plan~~a ~~and~~510(k) ~~perform~~to the ~~audit~~FDA tounless ~~obtain~~the ~~reasonable~~device ~~assurance~~is ~~about~~exempt ~~whether~~from the ~~financial~~510(k) ~~statements~~requirements ~~are~~of ~~free~~the ofFederal ~~material~~Food, ~~misstatement.~~Drug, ~~The~~and ~~Company is~~Cosmetic ~~not~~Act ~~required~~(the toAct) ~~have,~~and ~~nor~~does not ~~were~~exceed wethe ~~engaged~~limitations toof ~~perform,~~exemptions anfor ~~audit~~each of ~~its~~the ~~internal~~device ~~control~~classification ~~over~~regulations ~~financial~~(Section ~~reporting~~.9 ~~Our~~of ~~audits~~21 CFR Parts 862 through ~~include~~892, ~~consideration~~e.g., 21 CFR 862.9, 21 CFR 864.9, etc.). Under section 510(k) of ~~internal~~the ~~control~~FD&C ~~over~~Act, ~~financial~~a ~~reporting~~manufacturer asmust submit a ~~basis~~510(k) ~~for~~to FDA ~~designing~~at ~~audit~~least ~~procedures~~90 ~~that~~days ~~are~~before ~~appropriate in~~introducing, ~~the~~or ~~circumstances~~delivering for introduction, ~~but~~a ~~not~~device into interstate commerce for commercial distribution so the ~~purpose~~Agency ofcan ~~expressing~~determine anwhether ~~opinion~~or onnot the ~~effectiveness~~device ofmeets the ~~Company's~~criteria ~~internal~~for ~~control~~market ~~over~~clearance (Sections 510(k) and (n) of the ~~financial~~FD&C ~~reporting.~~Act ~~Accordingly,~~(21 weU.S.C. ~~express~~§§ no360(k) ~~such~~& ~~opinion~~(n))). AnThe ~~audit~~Agency ~~includes~~bases ~~examining,~~its decision on awhether ~~test~~the ~~basis,~~device ~~evidence~~is ~~supporting~~substantially ~~the~~equivalent ~~amounts~~(SE) ~~and~~to ~~disclosures~~a inlegally ~~the~~marketed ~~financial~~(predicate) ~~statements.~~device An(Section ~~audit~~513(i) ~~also~~of ~~includes~~the ~~assessing~~FD&C ~~the~~Act ~~accounting~~(21 ~~principles~~U.S.C. ~~used~~§ ~~and~~360c(i))). ~~significant~~The ~~estimates~~device ~~made~~cannot bybe ~~management,~~commercialized asuntil ~~well~~FDA asissues ~~evaluating~~an ~~the~~order ~~overall~~(510(k) ~~financial~~clearance) ~~statement~~stating ~~presentation.~~that Wethe ~~believe~~device ~~that~~has ~~our~~been ~~audits~~determined ~~provide~~to be aSE ~~reasonable~~(Section ~~basis~~513(f)(1) ~~for~~of ~~our~~the ~~opinion~~FD&C Act (21 U.S.C. § 360c(f)(1)))

InCurrently, ~~our~~we ~~opinion,~~do not know the ~~financial~~identity ~~statements~~of the manufacturer ~~referred~~of tothe ~~above~~UDT ~~present~~Cup. ~~fairly~~Our supplier, inInnovative ~~all~~Laboratory ~~material~~Solutions ~~respects,~~is the ~~financial~~only ~~position~~party ofwe ~~the~~are ~~Company,~~aware as of ~~November~~who ~~30,~~knows ~~2015~~the ~~and 2014~~identity ~~and~~of the manufacturer ~~results~~ of ~~its~~the ~~operations~~cup. ~~and~~We ~~its~~rely ~~cash~~in ~~flows~~totality ~~for~~that the ~~year~~manufacturer, ~~ended~~of ~~November~~which ~~30,~~we ~~2015~~do ~~and~~not ~~for~~know the ~~period~~identity ~~from November 25~~of, ~~2015~~is ~~(inception) through November 30, 2014~~ in ~~conformity~~ compliance with ~~accounting~~the ~~principles~~510(k) ~~generally~~requirements ~~accepted~~for in the ~~United~~UDT ~~States of America~~cup.

~~The~~ILS ~~accompanying~~has ~~financial~~informed ~~statements have~~us ~~been prepared assuming~~ that the ~~Company~~UDT ~~will~~cup ~~continue~~is ~~as a going concern. As discussed~~ in ~~Note~~compliance ~~3 to the financial statements,~~with the ~~Company~~above ~~has~~and ~~suffered~~the a510(k) ~~net~~clearance ~~loss,~~date ~~working~~of ~~capital~~the ~~deficiency,~~UDT ~~does~~Cup ~~not~~is ~~have~~December ~~assets~~19, ~~nor does it have operations or a source of revenue sufficient to cover its operation which raises substantial doubt about its ability to continue as a going concern~~2014. ~~Management's plans regarding those matters also are described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.~~

A 510(k) requires demonstration of substantial equivalence to another legally U.S. marketed device. Substantial equivalence means that the new device is at least as safe and effective as the predicate. As mentioned previously the ILS Cup is a device classified as a Rapid Single/sMulti-drug test Cup and Rapid Single/Multi-drug ~~MaloneBailey,~~Test ~~LLP~~Dipcard.

~~www~~A device is substantially equivalent if, in comparison to a predicate it: a.~~malonebailey~~ has the same intended use as the predicate; and b.~~com~~ has the same technological characteristics as the predicate; or c. has the same intended use as the predicate; and d. has different technological characteristics and the information submitted to FDA; e. does not raise new questions of safety and effectiveness; and f. demonstrates that the device is at least as safe and effective as the legally marketed device.

~~Houston~~Medical device manufacturers involved in the distribution of devices must follow certain requirements and regulations once devices are on the market. These include such things as tracking systems, ~~Texas~~reporting of device malfunctions, serious injuries or deaths, and registering the establishments where devices are produced or distributed. Postmarket requirements also include postmarket surveillance studies required under section 522 of the act as well as post-approval studies required at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. In accordance with Section 522 of the Federal Food, Drug and Cosmetic Act postmarket surveillance of a class II or class III device the UDT Cup may be required if the FDA. Should this occur the FDA will send a letter requiring it. For more information regarding such an FDA request please see here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=822.5.

~~February~~The 17Code of Federal Regulations, ~~2016~~Title 21, Part 201 encompasses certain requirements that must be on the labeling of any medical product which includes, but is not limited to, the name and place of business of the manufacturer, packer, or distributor, the directions for use, expiration date, and active ingredients in the product. We rely in totality on ILS, our supplier of the UDT Cup, to adhere to the appropriate product labeling so that the product is within the guidelines of Title 21, Part 201.

~~-F2-~~Our supplier of the UDT Cup, ILS has made previous sales of the UDT Cup to customers in the past, primarily in Florida. The customers comprised of a combination of health centers, rehabilitation clinics, and private parties.

~~Table~~We are only a distributor (reseller) of the UDT Cup. As a distributor of ~~Contents~~the UDT Cup we are not required to have FDA approvals due to the CLIA waivers that are present for each panel of the UDT Cup.

~~Opulent~~Our ~~Acquisition~~supplier Innovative Laboratory Solutions, ~~Inc.~~however, has obtained the following in order to act as a global supplier, importer, and exporter of the UDT Cup (Drug Of Abuse Cup):

~~BALANCE~~SBD #155350 ~~SHEETS~~FDA User Fee Organization # 394392 Approved 04/03/2015 under the (MDUFA) Medical Device User Fee Act

				As of November 30, 2015		As of November 30, 2014
ASSETS
TOTAL ASSETS			$	-	$	-
LIABILITIES AND STOCKHOLDERS’ DEFICIT
	CURRENT LIABILITIES:
		Accrued expenses		3,446		2,148
	Total Liabilities			3,446		2,148
	STOCKHOLDERS’ DEFICIT:
		Preferred stock ($.0001 par value, 20,000,000 shares authorized; none issued and outstanding as of November 30, 2015 and November 30, 2014)		-		-
		Common stock ($.0001 par value, 500,000,000 shares authorized, 20,000,000 shares issued and outstanding as of November 30, 2015 and November 30, 2014)		2,000		2,000
		Additional Paid in Capital		6,198		-
		Accumulated Deficit		(11,644)		(4,148)
	Total Stockholders' Deficit			(3,446)		(2,148)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT			$	-	$	-

-3-

~~The accompanying~~Table ~~notes to the financial statements are an integral part~~ of ~~these financial statements~~Contents

~~-F3-~~Launch and Growth Strategy:

~~Table~~We at Ihealthcare, Inc. intend to utilize web-based advertising in order to reach our intended market. We are currently in the exploration stages of ~~Contents~~ determining which internet media outlet will be preferable, but we have plans to consider, and perhaps implement, marketing campaigns via social media networks such as Facebook, Twitter, etc., online marketing platforms, news related websites, industry related websites, etc. We will also be listing our products on Amazon in order to take advantage of the worldwide presence and reach of Amazon in order to reach an even greater audience and sell our products to as many consumers as possible.

~~Opulent~~In addition to our online presence, we also are in the planning ~~Acquisition~~stages of a multimedia campaign which may include, ~~Inc~~but may not strictly be limited to, telemarketing, print media, making our presence known at trade shows and television advertisements. The exact details of our multimedia plan are currently in the exploration and planning stages.

~~STATEMENTS~~Our OFgrowth ~~OPERATIONS~~strategy is to spread awareness of our products, via the internet and potentially other sources, all cross the country, beginning in the south east, then moving north and eventually west. When, and if, we have developed a market for our products within the United States we will then evaluate the possibility of expanding to other countries throughout the world.

			For the year ended November 30, 2015		For the period from November 25, 2014 (inception) to November 30, 2014
Revenues
	Revenues	$	-	$	-
Operating Expenses
	General and administrative expenses		7,496		4,148
Total Operating Expenses			7,496		4,148
Net loss		$	(7,496)	$	(4,148)
Net loss per common share
	Basic and Diluted net loss per share of common stock	$	(0.00)	$	(0.00)
Weighted average number of common shares outstanding – Basic and Diluted			20,000,000		20,000,000

At this time we do not have not yet identified a definitive timeline as to the length of time it will take us to initialize or carry out the above growth strategy. We are currently investigating the costs that we will incur in carrying out the above endeavors to begin generating sales from our current product.

~~The~~We ~~accompanying~~believe we need to develop a more concrete marketing plan ~~notes~~so that we can sell the goods on a large scale (to more than one consumer from time to time). We also believe we need to hire additional staff of which we have begun to do so. To date we have hired what we refer to as an “SVP of Operations.” This individual is responsible for formulating our marketing plan moving forward, amending it as seen fit, contacting and facilitating relationships with potential wholesalers and overseeing any other sales employees we currently have or may hire in the ~~financial~~future. Currently ~~statements~~we have two sales team members that are ancommission ~~integral~~based. ~~part~~At this point in time none of ~~these~~our ~~financial~~sales ~~statements~~ have been a result of their efforts, and thus no commission has been paid at this time.

~~-F4-~~Other Business Activities

~~Table~~While our principal business remains the sale of ~~Contents~~UDT Cups, we will also, from time to time, evaluate the possibility of forming business partnerships, making acquisitions, and conducting various additional business activities. We, and our subsidiary, Ihealthcare Surgical, LLC, have formed several business partnerships at present which we hope will further our current business objectives and potentially provide our business with additional revenue streams.

~~Opulent~~On July 25, 2016 we, Ihealthcare, Inc., ~~Acquisition~~organized Ihealthcare Surgical, LLC, a Florida Limited Liability Company. The members of the LLC include Ihealthcare, Inc., and All in 1 Medical, LLC. Each of the aforementioned parties own 50% of the membership interests in Ihealthcare Surgical, LLC. All in 1 Medical, LLC is owned and operated by Mark Heffner, who is a non-affiliate of Ihealthcare, Inc.

~~STATEMENTS~~On OFAugust ~~CHANGES~~19, IN2016 ~~STOCKHOLDERS’~~Ihealthcare Surgical, LLC, entered ~~DEFICIT~~into and consummated a joint venture agreement with All In 1 Medical, LLC. The purpose of the joint venture agreement is to forge a relationship that through, to be determined means, will bring together both parties in an effort to sell, to be determined, medical products. Each party retains a 50% interest in the joint venture. Each party has also agreed to split profits and expenses equally that relate to the joint venture. The term of the joint venture agreement is through August 4, 2026. It may be renewed however, for an additional five year term if agreed upon by both parties. Each party of the joint venture agreement has agreed to contribute $500 for business purposes set forth in the joint venture agreement. Neither party has, as of the date of this report, contributed the $500 however, both parties intend to make such contribution after a joint bank account is opened up for the purpose of the joint venture. Per the aforementioned ASC 808 does not apply since the entity, is setup as a wholly owned subsidiary and ASC 323 would not apply since there is no consideration paid as November 30, 2016.

~~For~~On October 3, 2016 Ihealthcare Surgical, LLC entered into and consummated an agreement with Precision Spine, Inc., “Precision,” to act as Precision’s sales agent in regards to the sale of spinal implants and other medical products that are manufactured for or by Precision. Ihealthcare, Inc. is to receive a 40% commission on the sale of spinal implants for the fourth quarter of 2016 and effective January of 2017, 35%, +5% each quarter if Ihealthcare is able to generate sales of $300,000 or more in a quarterly period. ~~from~~For ~~November~~“Biologic” 25products as they are categorized in the agreement, ~~2014~~Ihealthcare ~~(inception)~~will ~~through~~receive ~~November~~a 30to be decided upon commission that is agreed upon by both parties at a later date. Regarding disposable single use instruments, ~~2015~~Ihealthcare, Inc. will receive a 20% commission for any sales generated on Precision’s behalf. On December 6, 2016 iHealthcare Surgical, LLC and Precision Spine, Inc. mutually agreed to the termination of the agreement entered into on October 3, 2016. There were no revenues generated under this agreement.

	Common Stock		Par Value Common Stock		Additional Paid-in Capital		Accumulated Deficit		Total
November 25, 2014 (Inception) -Shares issued for services rendered at $.0001 per share (par value)	20,000,000	$	2,000	$	-	$	-	$	2,000
Net loss for the period	-		-		-		(4,148)		(4,148)
Balance November 30, 2014	20,000,000	$	2,000	$	-	$	(4,148)	$	(2,148)
Contributed Expenses	-		-		6,198		-		6,198
Net Loss	-		-		-		(7,496)		(7,496)
Balance November 30, 2015	20,000,000	$	2,000	$	6,198	$	(11,644)	$	(3,446)

On October 10, 2016 our subsidiary, iHealthcare Surgical, LLC entered into an agreement with Gensano, LLC. Under the terms of the agreement iHealthcare Surgical, LLC will act as a sales agent for Gensano, LLC by attempting to sell products on their behalf. In this agreement iHealthcare Surgical, LLC will receive a sales commission which will be comprised of the difference between the price of Gensano’s products and the actual cost at which iHealthcare Surgical manages to sell the products. Gensano has set a fixed cost, per product, that they must receive from the sale of each item. IHealthcare Surgical, LLC will not directly purchase products from Gensano, and all shipping will be conducted directly from Gensano to the customer. There have been no revenues generated under this agreement to date.

~~The~~On November ~~accompanying~~25, ~~notes~~2016 toiHealthcare ~~financial~~Surgical, ~~statements~~LLC entered into an agreement with S1 Spine. Under the terms of the agreement S1 Spine has appointed iHealthcare Surgical, LLC to act as its sales agent to solicit orders for the products of S1 Spine. Sales are anto be ~~integral~~attempted, ~~part~~by iHealthcare Surgical LLC in Florida, Georgia, Nevada and New Mexico. In exchange for operating as the sales agent for S1 Spine, iHealtcahre Surgical shall receive a commission based upon the net invoice price of ~~these~~products ~~financial~~offered ~~statements~~for sale. There have been no revenues generated under this agreement to date.

~~-F5-~~On February 23, 2017 Ihealthcare, Inc. entered into an agreement with John Cook and Paul Pereira. Under the terms of the agreement John Cook and Paul Pereira will act as part time consultants for Ihealthcare, Inc. Their role shall pertain to assisting the Company with obtaining and structuring institutional financing from various commercial banks, investment banking firms, private equity firms and related financial and business issues. John Cook and Paul Pereira shall be compensated for their part time assistance as consultants through a combination of cash and stock incentives. John Cook and Paul Pereira shall be awarded a total of 10.00%, respectively, of Series B Preferred stock based upon acquisition milestones. The 10.00% to that point shall be Series B Preferred Stock, however, if they assist the Company in achieving gross revenues exceeding $200,000,000 then they will each be awarded an extra 2.5% of the Preferred Stock in a new class with the same rights as Series B. This would bring their total equity interest to 12.50% each, and 25.00% total.

~~Table of Contents~~ Competition

~~Opulent~~While we offer what we feel to be the most efficient and cost ~~Acquisition~~effective drug screening product on the market today, ~~Inc~~we do face intense competition from other Companies who offer similar products.

~~STATEMENTS~~Competing OFone ~~CASH~~step ~~FLOWS~~products (meaning one device with multiple drug screening panels) include the following: DrugConfirm Advanced [10 panel]; AmeriCup [12 panel]; ECO II [10 panel]; CLIA Screen [12 panel]; T-Cup [10 panel]; EZ Split Key Cup [10 panel]; CentralCheck [11 panel]; NxStep [12 panel]; and others.

				For the year ended November 30, 2015		For the period from November 25 (inception) to November 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
	Net loss		$	(7,496)	$	(4,148)
	Adjustments to reconcile net loss to net cash used in operating activities:
		Expenses contributed to capital		6,198		-
		Share based expenses		-		2,000
	Changes in current assets and liabilities:
		Accrued expenses	$	1,298	$	2,148
Net cash used in operating activities				-		-
		Increase (Decrease) in cash		-		-
		Beginning cash balance		-		-
		Ending cash balance	$	-	$	-
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
	Interest paid		$	-	$	-
	Income taxes paid		$	-	$	-

We believe the UDT Cup we offer to customers differs from most other drug screening products on the market and may serve as a better alternative to many such products due to the fact that it can provide test results in a lesser amount of time, one minute versus four to ten minutes for most competing products. Additionally, the UDT Cup has an internal seal that may prevent cross contamination of the urine sample when shaken or jostled during testing. This is a feature that most other competing drug screening kits do not have. The UDT Cup’s design is also designed in a way that can make it more suitable for use among both males and females. This however, is our own opinion. The UDT Cup also comes standard with a temperature strip included as part of the kit, something most other drug screening kits offer but only as an “add on feature” for an additional cost.

~~The accompanying notes to the financial statements are an integral part of these financial statements~~ Employees

~~-F6-~~Currently, we have a total of three full time employees, two of which are our officers and directors, collectively Noel Mijares, and David A. Bingaman. The third is our recent hire, Maureen Walsh, for the position of “SVP of Operations.” We do not have a formal employee agreement with Ms. Walsh. As mentioned above on this page the SVP of Operations is responsible for formulating our marketing plan moving forward, amending it as seen fit, contacting and facilitating relationships with potential wholesalers and overseeing any other sales employees we currently have or may hire in the future. Currently we have two sales team members that are commission based employees that work part time at this moment. For the time being we are familiarizing these employees with the product and having them work alongside our SVP of Operations.

~~Table~~Our full time employees including our officers and directors, currently devote and intend to continue to devote 40 hours per week towards the Company. In the future we intend to increase our sales staff however, the number of ~~contents~~ employees we would hire would depend on our current level of revenue, and cash available to do so. We plan to hire these employees on a need be basis that is currently unidentified.

~~Opulent Acquisition, Inc.~~-4-

~~NOTES TO~~Table ~~THE~~of ~~FINANCIAL STATEMENTS~~ Contents

~~November 30,~~Item ~~2015,~~1A. ~~and~~Risk ~~November 30, 2014~~ Factors.

~~Note 1~~Risks –Relating ~~Organization~~to ~~and~~Our ~~Description~~Company ofand ~~Business~~Our Industry

~~Opulent Acquisition,~~We ~~Inc.~~will ~~(the~~require ~~Company)~~additional ~~was~~funds ~~incorporated~~in ~~under~~ the ~~laws of the State of Delaware on November 25, 2014. The Company intends~~future to ~~serve~~achieve asour acurrent ~~vehicle~~business tostrategy ~~affect~~and anour ~~asset~~inability ~~acquisition,~~to ~~merger,~~obtain ~~exchange~~funding ofwill ~~capital~~cause ~~stock~~our ~~or other~~ business ~~combination~~to ~~with a domestic or foreign business~~fail. ~~As of November 30, 2015 the Company had not yet commenced any operations.~~

~~The~~We will need to raise additional funds through public ~~Company~~or ~~has~~private ~~elected~~debt ~~November~~or ~~30th~~equity sales in order to fund our future. These financings may not be available when needed. Even if these financings are available, it may be on terms that we deem unacceptable or are materially adverse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences, or other terms. Our inability to obtain financing would have an adverse effect on our ability to implement our current business plan and develop our product line, and as ~~its~~a ~~year~~result, ~~end~~could require us to diminish or suspend our operations and possibly cease our existence.

~~Note~~Even if we are successful in raising capital in 2the –future ~~Summary~~we will likely need to raise additional capital to continue and/or expand our operations. If we do not raise the additional capital, the value of ~~Significant~~any ~~Accounting~~investment ~~Policies~~in our Company may become worthless. In the event we do not raise additional capital from conventional sources, it is likely that we may need to scale back or curtail implementing our business plan.

~~Basis~~As of our most recent year end we had minimal cash and/or cash equivalents. As a result of ~~Presentation~~having minimal cash to fund our business we have, and continue to be, primarily reliant upon our Officers and Directors to fund our operations. We believe our officers and directors will continue to fund our operations for a period of twelve months although there is no guarantee that they will do so.

~~The Financial~~We ~~Statements and related disclosures~~ have ~~been~~generated ~~prepared~~only ~~pursuant~~minimal revenues to ~~the rules and regulations of the Securities and Exchange~~date ~~Commission~~since ~~(“SEC”)~~our inception. ~~The~~Our ~~Financial~~independent ~~Statements~~registered ~~have~~public ~~been prepared using the accrual basis of~~ accounting infirm, ~~accordance with~~MaloneBailey, ~~Generally~~LLP ~~Accepted~~has ~~Accounting~~issued ~~Principles~~a ~~(“GAAP”)~~going ofconcern ~~the~~opinion ~~United States (See Note 3) regarding the assumption~~in ~~that~~their ~~the~~audit ~~Company~~report isin aregards ~~“going~~to ~~concern”~~our operations.

~~Use~~In their audit report our PCAOB auditor MaloneBailey, LLP issued a going concern opinion in regards to our operations. The going concern was issued due to the fact we have suffered a net loss and do not have a source of ~~Estimates~~revenue sufficient to cover our operations which raises substantial doubt about our ability to continue. The going concern issued by our independent auditor may have a negative impact on the value of our common stock, although the extent of this negative impact is not known at this time. Additionally, we may have a more difficult time obtaining financing as a result of the going concern.

~~The preparation~~We ofare ~~financial~~a ~~statements~~start-up instage ~~conformity~~company. ~~with~~Our ~~generally~~ability ~~accepted~~to continue ~~accounting~~as ~~principles~~a ~~requires~~going ~~management~~concern tois ~~make~~dependent ~~estimates and~~upon ~~assumptions~~our ~~that~~ability ~~affect~~to ~~the~~commence ~~reported~~a ~~amounts~~commercially ofviable ~~assets~~operation and ~~liabilities~~to ~~and~~achieve ~~disclosure~~profitability. Since ofour ~~contingent~~inception ~~assets~~we have generated minimal revenues, and ~~liabilities at~~currently ~~the~~have ~~date~~only oflimited ~~the~~operations, ~~financial~~as ~~statements~~we ~~and~~are ~~the~~presently ~~reported~~in ~~amounts~~the planning stage of ~~revenues~~our ~~and~~business ~~expenses~~development ~~during~~as ~~the~~an ~~reporting~~exploration ~~period~~stage company. InThese ~~the opinion~~factors ofraise ~~management,~~substantial ~~all~~doubt ~~adjustments~~about ~~necessary~~our inability to ~~order~~continue toas ~~make~~a ~~the~~going ~~financial~~concern. ~~statements~~We may not ~~misleading~~be ~~have~~able ~~been~~to ~~included. Due~~generate torevenues in the ~~minimal~~future ~~level~~and ofas ~~operations,~~a result the ~~Company~~value ~~has~~of ~~not~~our ~~had~~common tostock may ~~make~~become ~~material~~worthless. ~~assumptions~~There orare ~~estimates~~no ~~other~~assurances ~~than~~that ~~the~~we ~~assumption that~~will ~~the~~be ~~Company~~successful isin araising ~~going~~additional ~~concern.~~capital ~~Actual~~or ~~results~~successfully ~~could~~developing and ~~differ~~commercializing ~~from~~our ~~those~~products ~~estimates~~and becoming profitable.

~~Cash~~We hold the distribution rights to the UDT Cup, ~~Equivalents~~but we rely on the services of a third party supplier (ILS) in order to supply the products we offer for sale. ILS has the right to control who manufacturers the product, the UDT Cup, which we offer for resale.

~~The~~Due to the fact that we rely upon ILS in order to ~~Company~~supply ~~considers~~the ~~all~~UDT ~~highly~~Cups ~~liquid~~which ~~investments~~our ~~with~~company anis ~~original~~currently ~~maturity~~selling we face inherent risks due to the fact that we do not hold the patents or manufacturing rights to the product. If there is a disruption in the supply of ~~three~~UDT ~~months~~Cups caused by any number of situations which could arise with ILS, then we may have difficulty successfully implementing our business plan or ~~less~~meeting the demand for our products when ~~purchased~~we have commenced operations. These disruptions could include, but are not strictly limited to, beshipping ~~cash~~difficulties ~~equivalents.~~or setbacks, ~~Cash~~price ~~and~~increases ~~cash~~which ~~equivalents~~would atrequire ~~November~~renegotiation 30of terms, ~~2015~~manufacturing difficulties on the part of ILS, etc. Additionally, should ILS go out of business then we will be forced to find an alternative product for sale, and ~~2014~~an ~~were~~alternative $0manufacturer, which could delay our business operations substantially or force us to cease operations entirely.

~~Income~~ILS is solely responsible for the shipping of ~~Taxes~~the UDT Cups.

~~The Company~~We ~~accounts~~will ~~for~~not ~~income~~be ~~taxes~~responsible ~~under~~for ~~ASC~~shipping ~~740, “Income Taxes.” Under~~ the ~~asset and liability method~~UDT ofCups ~~ASC~~to ~~740,~~any ~~deferred~~consumers. ~~tax~~ILS ~~assets~~is ~~and~~solely ~~liabilities~~responsible ~~are recognized~~ for ~~the~~shipping ~~future tax consequences attributable to differences between~~ the ~~financial~~UDT ~~statements~~Cups ~~carrying amounts of existing assets~~ and ~~liabilities~~any ~~and~~disruptions ~~their~~or ~~respective~~hold ~~tax~~ups ~~bases. Deferred~~in ~~tax assets~~relation ~~and liabilities are measured using enacted tax rates expected~~ to ~~apply to taxable income in~~ the ~~years in which those temporary~~shipping ~~differences~~of ~~are~~the ~~expected~~UDT toCups becould ~~recovered~~cause ~~or settled. The effect on deferred tax assets and liabilities of~~ a ~~change~~disruption inthat ~~tax rates~~will isnegatively ~~recognized~~impact inour ~~income in the period the enactment occurs~~operations. A ~~valuation~~Consumers ~~allowance~~may islose ~~provided~~faith ~~for~~in ~~certain~~our ~~deferred~~ability to ~~tax~~have ~~assets~~UDT ifCups itreliably isshipped ~~more~~through ~~likely~~situations ~~than not~~ that ~~the~~are ~~Company~~beyond ~~will~~our ~~not realize tax assets through future operations~~control. ~~No deferred tax assets or liabilities were recognized at November 30, 2015 or November 30, 2014.~~

~~Basic~~Due to the fact that we do not have a concrete ~~Earnings~~advertising ~~(Loss)~~plan ~~Per~~we ~~Share~~may not see the sales we anticipate if our advertising plan is not as effective as we plan.

~~The Company~~We ~~computes~~are ~~basic and diluted earnings per share amounts~~ in ~~accordance~~the ~~with~~planning ~~ASC~~stages ~~Topic~~of ~~260, Earnings~~our ~~per Share.~~advertising ~~Basic~~strategy, ~~earnings~~and ~~per~~as ~~share~~such iswe ~~computed~~do bynot ~~dividing~~have ~~net~~a ~~income~~definitive ~~(loss)~~plan ~~available~~for tohow ~~common~~we ~~shareholders~~will byconduct ~~the~~our ~~weighted~~marketing ~~average number of common shares outstanding during the reporting period~~efforts. ~~Diluted~~We ~~earnings~~plan ~~per~~to ~~share~~utilize ~~reflects~~internet media ~~the~~outlets, ~~potential~~and ~~dilution~~social ~~that~~media, ~~could occur~~but ifour ~~stock~~plans ~~options~~need ~~and other commitments~~ to ~~issue~~be ~~common~~further ~~stock~~developed ~~were~~before ~~exercised~~we orcan ~~equity~~begin ~~awards~~implementing ~~vest~~them ~~resulting~~fully. inAs ~~the issuance~~such, ofwe ~~common~~may ~~stock~~see ~~that~~fewer ~~could~~sales ~~share~~than inwe ~~the~~anticipate ~~earnings~~if ofour ~~the~~marketing ~~Company. As of November 30~~plan, ~~2015~~once ~~and 2014~~implemented, ~~there~~is ~~were~~not noas ~~common~~effective ~~stock equivalents~~as orwe ~~options outstanding~~plan.

~~Fair Value~~We cannot identify the manufacturer of ~~Financial~~the ~~Instruments~~UDT Cup.

~~The~~Due to our agreement with ILS, whereby they provide and ~~Company’s~~will ~~balance~~continue ~~sheet~~to ~~includes~~provide ~~certain~~us ~~financial~~with ~~instruments~~UDT Cups, they have withheld the name of the manufacturer of the UDT Cup. ~~The~~ILS ~~carrying~~acts ~~amounts~~as the distributor who supplies us with physical inventory. Due to the fact that we have no means through which we can identify the manufacturer there are inherent related risks. We rely on ILS to verify that the manufacturer complies with applicable rules and regulations pertaining to a manufacturer of ~~current~~a ~~assets~~medical device and ~~current~~we ~~liabilities~~can not directly verify this ourselves. While we do not believe we are subject to ~~approximate~~any ~~their~~potential ~~fair~~product ~~value~~liability, because ofwe believe that it will be either the ~~relatively~~manufacturer ~~short~~or ~~period~~ILS ofwho ~~time~~will ~~between~~be responsible for product liability, we cannot accurately assess the ~~origination~~manufacturer’s offinancial ~~these~~ability ~~instruments~~to ~~and~~compensate ~~their~~us for any potential liabilities ~~expected~~related ~~realization~~to the product.

~~ASC 820,~~-5- Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

·Table ~~Level~~of 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. · Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. · Level 3 - Inputs that are both significant to the fair value measurement and unobservable.Contents

~~Fair value~~Our ~~estimates~~growth ~~discussed~~strategy ~~herein~~is ~~are~~untested, ~~based~~unproven, ~~upon certain market assumptions~~ and ~~pertinent information available to management~~ as of ~~November 30, 2015 and 2014. The respective carrying value~~ of ~~certain~~this ~~on-balance-sheet financial instruments approximated their~~point ~~fair~~in ~~values~~time ~~due~~not tofully ~~the short-term nature of these instruments~~developed. ~~These financial instruments include accrued expenses.~~

~~Share-based~~We intend to grow our business starting in the South Eastern States ~~Expense~~of the United States, and from there spread outward into the North and eventually westward until we spread throughout the entire Country, at which point we will begin exploring international options. However, our exact strategy for how we will grow in this manner is currently in development, alongside our marketing plan, and we can offer no assurances that we will be effective in growing at the rate we anticipate, which could result in lower profit margins, if any.

~~ASC 718,~~We ~~“Compensation~~have –a ~~Stock~~limited ~~Compensation”,~~operating ~~prescribes~~history ~~accounting~~that ~~and~~you ~~reporting~~can ~~standards~~use ~~for~~to ~~all share-based~~evaluate ~~payment~~us, ~~transactions~~and inthe ~~which~~likelihood ~~employee~~of ~~services~~our ~~are~~success ~~acquired.~~must ~~Transactions~~be ~~include~~considered ~~incurring~~in ~~liabilities,~~light orof ~~issuing~~the orproblems, ~~offering to issue shares~~expenses, ~~options~~difficulties, ~~and~~complications ~~other equity instruments such as employee stock ownership plans~~ and ~~stock appreciation rights. Share-based~~delays ~~payments~~that towe ~~employees,~~may ~~including~~encounter ~~grants~~because ofwe ~~employee stock options,~~ are ~~recognized~~a assmall ~~compensation~~developing ~~expense in the financial statements based on their fair values~~company. ~~That~~As ~~expense~~a isresult, ~~recognized~~we ~~over~~may ~~the~~not ~~period~~be ~~during~~profitable ~~which~~and anwe ~~employee~~may isnot ~~required~~be toable ~~provide services~~to ingenerate ~~exchange~~sufficient ~~for~~revenue ~~the~~to ~~award,~~develop ~~known~~ as ~~the~~we ~~requisite~~have ~~service period (usually the vesting period)~~planned.

~~The Company~~We ~~accounts~~have ~~for~~only ~~stock-based~~recently ~~compensation~~adopted ~~issued~~a tobona ~~non-employees~~fide ~~and~~business ~~consultants~~plan. inWe ~~accordance~~have limited ~~with~~financial ~~the~~resources ~~provisions~~and limited assets. The likelihood of ~~ASC 505-50,~~our ~~“Equity~~success –must ~~Based~~be ~~Payments~~considered toin ~~Non-Employees.” Measurement~~light of ~~share-based~~the ~~payment~~expenses ~~transactions~~and difficulties ~~with~~in ~~non-employees~~development isof ~~based~~a oncustomer ~~the~~base ~~fair~~nationally, ~~value~~attaining ofand ~~whichever~~retaining iscustomers ~~more~~and ~~reliably~~obtaining ~~measurable: (a)~~financing ~~the~~to ~~goods~~meet orthe ~~services~~needs ~~received;~~of our orplan ~~(b)~~of ~~the~~operations. ~~equity~~Since ~~instruments~~we ~~issued. The~~have ~~fair~~a ~~value~~limited ofoperating ~~the~~history ~~share-based~~we ~~payment~~may ~~transaction~~not isbe ~~determined~~profitable atand ~~the~~we ~~earlier~~may not be able to generate sufficient ofrevenues ~~performance~~to ~~commitment~~meet ~~date~~our orexpenses ~~performance~~and ~~completion~~support ~~date~~our anticipated activities.

~~The~~We are an early stage company ~~had~~with noan unproven business strategy ~~stock-based~~and ~~compensation~~may ~~plans~~never atbe ~~November~~able ~~30,~~to ~~2015~~fully ~~and~~implement ~~2014~~our business plan or achieve profitability.

~~Share~~We are at an early stage of development of our operations as a company. We have only recently started to operate business activities, and have generated minimal revenue from such operations. A commitment of substantial resources to conduct time-~~based~~consuming ~~expense~~research ~~for~~in many respects will be required if we are to complete the development ~~twelve~~of ~~months~~our ~~ended~~company ~~November~~into ~~30,~~one ~~2015~~that ~~was~~is $0more profitable. There can be no assurance that we will be able to fully implement our business plan at reasonable costs or successfully operate. We expect it will take several years to implement our business plan fully, if at all.

~~Share-based~~Our ~~expense~~limited ~~for~~operating ~~the for~~history ~~the~~makes ~~period~~it ~~from~~difficult ~~November~~for ~~25,~~us ~~2014~~to ~~through~~accurately forecast ~~November~~net ~~30,~~sales ~~2014~~and ~~was~~appropriately ~~$2,000~~plan our expenses.

~~-F7-~~We have a very limited operating history. As a result, it is difficult to accurately forecast our net sales and plan our operating expenses. This inability could cause our net income, if there is any income at all, in a given quarter to be lower than expected.

~~Table~~We operate in a highly competitive environment, and if we are unable to compete with our competitors, our business, financial condition, results of ~~Contents~~operations, cash flows and prospects could be materially adversely affected.

~~Related~~We operate in a highly competitive environment. Our competition ~~Parties~~includes all other companies that are in the business of the drug screening market. A highly competitive environment could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.

~~The Company~~Because ~~follows~~we ~~ASC~~are ~~850, Related~~small ~~Party~~and ~~Disclosures~~do not have much capital, ~~for~~ ~~the~~our ~~identification~~marketing campaign ofmay ~~related~~not ~~parties~~be ~~and~~enough ~~disclosure of~~to ~~related~~attract ~~party~~sufficient ~~transactions~~customers to operate profitably. If we do not make a profit, we will suspend or cease operations.

~~Recent~~Due ~~Accounting~~to the fact we are small and do not have much capital, we must ~~Pronouncements~~limit our marketing activities and may not be able to make our product known to potential customers. Because we will be limiting our marketing activities, we may not be able to attract enough customers to operate profitably. If we cannot operate profitably, we may have to suspend or cease operations.

InWe ~~August~~expect ~~2014,~~our ~~FASB~~quarterly ~~issued~~financial ~~Accounting Standards~~results ~~Update (ASU) No. 2014-15, Presentation of Financial Statements – Going Concern; Disclosures of Uncertainties about an Entity’s Ability~~ to ~~Continue as a Going Concern~~fluctuate. The amendments in this update provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted but not required; at this time we are not early adopting. As the objective of this accounting standard is to provide guidance on the disclosure of uncertainties about an entity’s ability to continue as a going concern, the adoption of this standard is not expected to impact our financial position or results of operations.

InWe ~~June~~expect ~~2014, the~~our ~~FASB~~net ~~issued~~sales ~~ASU~~and ~~2014-10,~~operating ~~Development~~results ~~Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment~~ to ~~Variable~~vary ~~Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove~~significantly ~~all incremental financial reporting requirements~~ from ~~U.S.~~quarter ~~GAAP~~to ~~for~~quarter ~~development~~due ~~stage entities and also eliminate an exception provided~~ to ~~development stage entities in Topic 810, Consolidation, for determining whether an entity is~~ a ~~variable~~number ~~interest entity on the basis~~ of ~~the amount of investment equity that is at risk. These amendments are effective for annual reporting periods beginning after December 15~~factors, ~~2014,~~including ~~and~~unexpected ~~interim~~changes periods therein, with early application permitted. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). We early adopted this pronouncement. As the objective of the amendments in this update is to improve financial reporting by reducing the cost and complexity associated with the incremental reporting requirements for development stage entities our early adoption of this guidance has not impacted our financial position or results of operations.:

~~Note 3~~• –Demand ~~Going~~for ~~Concern~~our drug screening product(s);

~~The Company’s~~• ~~financial~~Our ~~statements~~ability ~~are prepared using accounting principles generally accepted in the United States of America applicable~~ to aobtain ~~going~~new, ~~concern that contemplates the realization of assets~~ and ~~liquidation~~retain ~~of liabilities in the normal course~~existing, ~~of business.~~customers;

~~The Company~~• ~~demonstrates~~Our ~~adverse conditions that raise substantial doubt about the Company's~~ ability to ~~continue~~manage asour a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, negative cash flow from operating activities, and other adverse key financial ratios.services;

~~The Company~~• ~~has~~General ~~not~~economic established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management's plan will be successful.conditions;

~~The financial~~• ~~statements~~Advertising ~~do not include any adjustments relating to the recoverability~~ and ~~classification~~other ofmarketing ~~recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern~~costs.

~~-F8-~~ As a result of the variability of these and other factors, our operating results in future quarters may be below the expectations of public market analysts and investors.

~~Table of Contents~~-6-

~~Note~~Table 4of ~~– Accrued Expenses~~Contents

~~Accrued~~Our ~~expenses~~future ~~totaled $3,446~~success ~~and~~is ~~$2,148~~dependent aton ~~November~~our ~~30,~~implementation ~~2015~~of ~~and~~our business ~~November~~plan. ~~30,~~We ~~2014,~~have ~~respectively~~many ~~for general~~significant ~~and~~steps ~~administrative~~still ~~expenses~~to take.

~~Note~~Our 5success –will depend on large part in our success in achieving ~~Commitments~~several important steps in the implementation of our business plan, including the following: acquiring business information, development of a customer base, development of relationships with consumers, and ~~Contingencies~~management of business process. If we are not successful, we will not be able to fully implement or expand our business plan.

~~The~~Our ~~Company~~growth ~~follows~~will ~~ASC~~place ~~450-20, Loss Contingencies, to report~~significant ~~accounting~~strains ~~for~~on ~~contingencies. Liabilities~~our for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimatedresources. ~~There were no commitments or contingencies as of November 30, 2015 and 2014.~~

~~Note~~The 6Company -is ~~Income~~currently ~~Taxes~~in the exploration stage, with only limited operations, and has generated only minimal revenue since inception. The Company's growth, if any, is expected to place a significant strain on the Company's managerial, operational and financial resources. Moving forward, the Company's systems, procedures or controls may not be adequate to support the Company's operations and/or the Company may be unable to achieve the rapid execution necessary to successfully implement its business plan. If the Company is unable to manage growth effectively, the Company's business, results of operations and financial condition will be adversely affected.

~~The~~Our ~~Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in~~ future ~~periods.~~success ~~The tax benefit for the period presented~~ is ~~offset by a valuation allowance established against deferred tax assets arising from the net operating losses~~dependent, ~~the~~in ~~realization of which could not be considered more likely than not. In future periods~~part, ~~tax~~on ~~benefits~~the performance and ~~related~~continued ~~deferred~~services ~~tax assets will be recognized when management considers realization~~ of ~~such~~Noel ~~amounts to be more likely than not. Due to the change in ownership provisions of the Tax Reform Act of 1986~~Mijares, ~~net~~our ~~operating~~Chief ~~loss~~Executive ~~carryforwards for~~Officer ~~Federal~~as ~~income~~well ~~tax~~as ~~reporting~~David ~~purposes~~A. ~~are~~Bingaman ~~subject~~our toChief ~~annual~~Operating ~~limitations~~Officer. ~~Should~~Without their acontinued ~~change in ownership occur~~service, ~~net~~we ~~operating loss carryforwards~~ may be ~~limited~~forced as to ~~use~~interrupt inor ~~future~~eventually ~~years~~cease our operations.

AsWe ofare ~~November~~presently ~~30,~~dependent ~~2015,~~to ~~the Company has incurred~~ a ~~net~~great ~~loss~~extent ~~carryforward~~upon ofthe ~~approximately $11~~experience,~~644~~ abilities ~~which~~and ~~resulted~~continued inservices aof ~~net~~both ~~operating~~Noel ~~loss~~Mijares ~~for~~and ~~income~~David ~~tax purposes~~A. ~~NOLs~~ ~~begin expiring in 2034~~Bingaman. The loss ~~results~~of ineither ~~a deferred tax asset~~ of ~~approximately~~their ~~$4,775~~services atwould ~~the~~delay ~~effective statutory rate~~our ofbusiness ~~35%.~~operations ~~The deferred tax asset has been off-set by an equal valuation allowance~~substantially.

	November 30,
	2015		2014
Deferred tax asset, generated from net operating loss at statutory rates	$	3,375	$	752
Valuation allowance		(3,375)		(752)
	$	—	$	—

Our President and CEO, Noel Mijares is also the President and CEO of Pharma Health Corp., Unisources Discovery and The Subpoena Company. Mr. Mijares’s other business interests may result in him being unable to devote enough hours to the Company to further advance operations.

~~The~~Our ~~reconciliation~~President and CEO, Noel Mijares is also the President and CEO of Pharma Health Corp., Unisources Discovery and The Subpoena Company. Mr. Mijares’s other business interests may result in him being unable to devote enough hours to the Company to further advance operations. Despite Mr. Noel Mijares’s ~~effective~~other ~~income~~business ~~tax~~ventures ~~rate~~he believes he is still able to devote 40 hours per week to the ~~federal~~Company’s ~~statutory~~operations ~~rate~~however, there is the possibility that he may not be able to do so. If this were to occur it could negatively impact our operations and could cause our results of operations to suffer as ~~follows:~~a result.

Federal income tax rate	35.0	%
Increase in valuation allowance	(35.0	%)
Effective income tax rate	0.0	%

Due to Article IX of our Certificate of Incorporation investors may have difficulty bringing any action against us in a judicial forum.

~~-F9-~~Article IX of our Certificate of Incorporation states that “unless we, the “Company” also referred to herein as “the Corporation” consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the corporation, (2) any action asserting a claim of breach of a fiduciary duty owed by, or other wrongdoing by, any director, officer, employee or agent of the corporation to the corporation or the corporation’s stockholders, (3) any action asserting a claim arising pursuant to any provision of the General Corporation Law or the corporation’s Restated Certificate of Incorporation or Bylaws, (4) any action to interpret, apply, enforce or determine the validity of the corporation’s Restated Certificate of Incorporation or Bylaws or (5) any action asserting a claim governed by the internal affairs doctrine, in each such case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the corporation shall be deemed to have notice of and consented to the provisions of this ARTICLE IX. Due to this provision, if a shareholder does not reside in Delaware then they may face difficulty bringing any action against us in a judicial forum due to the fact that all such claims must be made in the Court of Chancery of the State of Delaware. In addition to the potential inconvenience of physical location, shareholders may find this choice of forum inconvenient for any number of reasons which are subjective to the shareholder(s). This exclusive forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes. This may discourage lawsuits with respect to such claims against the company and its officers, directors or other employees.

~~Table~~The recently enacted JOBS Act will allow the Company to postpone the date by which it must comply with certain laws and regulations intended to protect investors and to reduce the amount of ~~Contents~~information provided in reports filed with the SEC.

~~Note~~The 7recently –enacted ~~Shareholder~~JOBS Act is intended to reduce the regulatory ~~Equity~~burden on “emerging growth companies”. The Company meets the definition of an “emerging growth company” and so long as it qualifies as an “emerging growth company,” it will, among other things:

~~Preferred~~-be ~~Stock~~ exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that its independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting;

~~The~~-be ~~authorized~~exempt ~~preferred~~from ~~stock~~the of"say on pay” provisions (requiring ~~the~~a ~~Company~~non-binding ~~consists~~shareholder vote to approve compensation of ~~20,000,000~~certain ~~shares~~executive ~~with~~officers) and the "say on golden parachute” provisions (requiring a ~~par~~non-binding ~~value~~shareholder ofvote ~~$0.0001.~~to ~~The~~approve ~~Company~~golden ~~has~~parachute ~~not~~arrangements ~~issued~~for ~~any~~certain ~~shares~~executive asofficers in connection with mergers and certain other business combinations) of ~~November~~The ~~30,~~Dodd-Frank Wall Street Reform and Consumer Protection Act ~~2015~~(the “Dodd-Frank Act”) and ~~2014.~~certain disclosure requirements of the Dodd-Frank Act relating to compensation of Chief Executive Officers;

~~Common~~-be ~~Stock~~permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and instead provide a reduced level of disclosure concerning executive compensation; and

~~The~~-be ~~authorized~~exempt ~~common~~from ~~stock~~any ofrules ~~the Company~~that ~~consists~~may ofbe ~~500,000,000~~adopted ~~shares~~by ~~with~~the aPublic ~~par~~Company Accounting ~~value~~Oversight ofBoard ~~$0.0001.~~(the ~~There~~“PCAOB”) ~~were~~requiring ~~20,000,000~~mandatory ~~shares~~audit offirm ~~common~~rotation ~~stock~~or ~~issued~~a ~~and~~supplement ~~outstanding as~~to ofthe ~~November~~auditor’s report ~~30,~~on ~~2015~~the ~~and~~financial ~~2014~~statements.

Although the Company is still evaluating the JOBS Act, it currently intends to take advantage of all of the reduced regulatory and reporting requirements that will be available to it so long as it qualifies as an “emerging growth company”. The Company ~~does~~has elected not ~~have~~to ~~any~~opt ~~potentially~~out of the extension of time to comply ~~dilutive~~with ~~instruments~~new asor revised financial accounting standards available under Section 102(b)(1) of ~~November~~the 30JOBS Act. Among other things, ~~2015~~this means that the Company's independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of the Company's internal control over financial reporting so long as it qualifies as an “emerging growth company”, which may increase the risk that weaknesses or ~~2014~~deficiencies ~~and~~in the internal control over financial reporting go undetected. Likewise, ~~thus~~so long as it qualifies as an “emerging growth company”, ~~anti-dilution~~the ~~issues~~Company ~~are~~may elect not ~~applicable~~to provide certain information, including certain financial information and certain information regarding compensation of executive officers, which would otherwise have been required to provide in filings with the SEC, which may make it more difficult for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market price of its common stock may be adversely affected.

OnNotwithstanding ~~November~~the 25above, ~~2014~~we ~~the~~are ~~Company~~also currently a “smaller ~~issued~~reporting 20company”,~~000~~ meaning that we are not an investment company,~~000~~ an asset-backed issuer, or a majority-owned subsidiary of ~~its~~a parent company that is not a smaller reporting company and have a public float of less than $075 million and annual revenues of less than $50 million during the most recently completed fiscal year.~~0001~~ ~~par~~In ~~value~~the ~~common~~event ~~stock~~that we are still considered a “smaller reporting company”, at $0such time are we cease being an “emerging growth company”, the disclosure we will be required to provide in our SEC filings will increase, but will still be less than it would be if we were not considered either an “emerging growth company” or a “smaller reporting company”.~~0001~~ ~~per~~Specifically, ~~share~~similar ~~and~~to ~~totaling~~“emerging $2growth companies”,~~000~~ “smaller reporting companies” are able to provide simplified executive compensation disclosures in their filings; are exempt from the ~~former~~provisions ~~sole~~of ~~officer/director/shareholder~~Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting; and have certain other decreased disclosure obligations in their SEC filings, including, among other things, being required to provide only two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as an “emerging growth company” or “smaller reporting company” may make it harder for ~~services~~investors to analyze the Company’s results of operations and financial prospects.

~~Pertinent~~We ~~Rights~~are an “emerging growth company” under the JOBS Act of 2012, and ~~Privileges~~we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

~~Holders~~We ofare ~~shares~~an of“emerging ~~common~~growth ~~stock~~company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are ~~entitled~~applicable to ~~one~~other ~~vote~~public companies ~~for~~that ~~each~~are ~~share~~not ~~held~~“emerging growth companies” including, but not limited to, benot ~~used~~being atrequired ~~all~~to ~~stockholders’~~comply ~~meetings~~with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and ~~for~~proxy ~~all~~statements, ~~purposes~~and ~~including~~exemptions from the requirements of holding a nonbinding advisory ~~election~~vote on executive compensation and shareholder approval of ~~directors~~any golden parachute payments not previously approved. ~~Common~~We cannot predict if investors will find our common stock ~~does~~less ~~not~~attractive ~~have~~because ~~cumulative~~we ~~voting~~may ~~rights.~~rely ~~Nor~~on ~~does~~these itexemptions. ~~have~~If ~~preemptive~~some orinvestors ~~preferential~~find ~~rights~~our common tostock ~~acquire~~less orattractive ~~subscribe~~as ~~for~~a ~~any~~result, ~~unissued~~there ~~shares~~may ofbe ~~any~~a ~~class~~less ofactive trading market for our common stock and our stock price may be more volatile.

~~Additional~~In ~~Paid~~addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In ~~Capital~~other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates.

~~Total~~We ~~amounts~~will ~~contributed~~remain toan ~~additional paid~~“emerging ingrowth ~~capital~~company” for ~~the~~up to ~~periods~~five ~~ended~~years, ~~November~~although ~~30,~~we ~~2015~~will ~~and~~lose ~~November~~that ~~30,~~status ~~2014~~sooner ~~totaled~~if our revenues exceed $61 billion,~~198~~ ~~and~~if we issue more than $01 billion in non-convertible debt in a three year period, ~~respectively.~~or ~~(Note~~if 8)the market value of our common stock that is held by non-affiliates exceeds $700 million.

~~Note 8 – Related~~-~~Party Transactions~~7-

~~Common~~Table ~~stock~~of Contents

~~On November 25, 2014 the Company~~Risks ~~issued~~Relating ~~20,000,000 of its $0.0001 par value common stock at $0.0001 per share and totaling $2,000~~ to the ~~former~~Company’s ~~sole office/director/shareholder for services.~~Securities

~~Additional~~We may never have a public market for ~~paid~~our common stock or may never trade on a recognized exchange. Therefore, you may be unable to liquidate your investment in ~~capital~~our stock.

~~During~~There ~~the year~~is ~~ended~~no ~~November~~established ~~30,~~public ~~2015,~~trading market for our ~~former~~securities. ~~sole~~Our ~~officer/director/shareholder~~shares ~~contributed~~are ~~additional~~not ~~paid~~and inhave ~~capital~~not inbeen ~~the~~listed ~~amount of~~or ~~$6,198~~quoted toon ~~fund~~any ~~operating~~exchange ~~expenses~~or quotation system.

~~Total~~In ~~amounts~~order ~~contributed~~for atour ~~November~~shares to be quoted, a 30market maker must agree to file the necessary documents with the National Association of Securities Dealers, ~~2015~~which ~~and~~operates ~~2014~~the OTCBB. ~~totaled~~In $6addition,~~198~~ it is possible that such application for quotation may not be approved and ~~none~~even if approved it is possible that a regular trading market will not develop or that if it did develop, ~~respectively~~will be sustained. In the absence of a trading market, an investor may be unable to liquidate their investment.

~~Note~~We 9may, –in ~~Subsequent~~the ~~Events~~ future, issue additional shares of our common stock, which may have a dilutive effect on our stockholders.

~~Following~~Our ~~our~~Certificate ~~fiscal~~of ~~year~~Incorporation ~~end~~authorizes the issuance of 143,500,000 shares of common stock, of which 1,000,000 shares are issued and outstanding as of November 30, ~~2015~~2016. The future issuance of our common shares may result in substantial dilution in the ~~following~~percentage ~~material~~of ~~events~~our common shares held by our then existing stockholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have ~~occurred:~~the effect of diluting the value of the shares held by our investors, and might have an adverse effect on any trading market for our common stock.

OnWe ~~January~~may ~~14,~~issue ~~2016 Mr. Jeffrey DeNunzio, the sole shareholder of the Company transferred to iHealthcare, Inc., 20,000,000~~ shares of ~~our~~preferred ~~common~~ stock ~~which represents all~~ ofin ~~our issued and outstanding shares. Noel Mijares and David A. Bingaman are~~ the ~~controlling~~future ~~shareholders~~that ofmay ~~iHealthcare, Inc.,~~adversely aimpact ~~Florida~~your ~~corporation.~~rights ~~Mr.Mijares~~as ~~owns~~holders ~~62.5% and Mr. Bingaman owns 37.5%~~ of ~~the~~our ~~issued~~common ~~and outstanding shares of iHealthcare, Inc~~stock.

OnOur ~~January~~Certificate of 14Incorporation authorizes us to issue 1, ~~2016~~500,000 Mrshares of Series A and 5,000,000 Series B Preferred Stock. ~~Jeffrey~~Each ~~DeNunzio~~holder Preferred ~~resigned~~B asStock ~~Chief~~shall ~~Executive~~have ~~Officer,~~the ~~Chief~~right ~~Financial~~to ~~Officer,~~one ~~President~~(1) vote per share of held of record by such holder and each holder of Series A Preferred Stock shall have the right to one hundred (100) votes per share of Series A Preferred Stock. Currently, ~~Secretary~~we have no shares of preferred stock outstanding, ~~Treasurer~~however ~~and~~the ~~Director~~issuance of any of our preferred stock may influence the value of your investment.

OnWe ~~January 14,~~do ~~2016,~~not ~~Mr.~~currently ~~Noel~~intend ~~Mijares~~to ~~was~~pay ~~appointed~~dividends ason ~~Chairman~~our ofcommon ~~the~~stock ~~Board~~and ofconsequently ~~Directors,~~your ~~Chief~~ability ~~Executive~~to ~~Officer,~~achieve ~~and~~a ~~President~~return on your investment will depend on appreciation in the price of our common stock.

OnWe ~~January~~have ~~14,~~never declared or paid any cash ~~2016,~~dividends ~~Mr.~~on ~~David~~our Acommon stock and do not currently intend to do so for the foreseeable future. ~~Bingaman~~We ~~was~~currently ~~appointed~~intend asto ~~Chief~~invest ~~Operating~~our future ~~Officer~~earnings, ~~Vice~~if ~~President~~any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future and ~~Secretary~~the success of an investment in shares of our common stock will depend upon any future appreciation in its value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.

We may be exposed to potential risks resulting from requirements under Section 404 of the Sarbanes-~~F10-~~Oxley Act of 2002.

~~Table~~As a reporting company we are required, pursuant to Section 404 of ~~Contents~~the Sarbanes-Oxley Act of 2002, to include in our annual report our assessment of the effectiveness of our internal control over financial reporting. We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees.

~~Item~~We do not currently have independent audit 9or compensation committees. ~~Changes~~As ina ~~and~~result, ~~Disagreements~~our directors have the ability, among other things, to determine their own level of compensation. Until we comply with ~~Accountants~~such oncorporate ~~Accounting~~governance measures, regardless of whether such compliance is required, the absence of such standards of corporate governance may leave our stockholders without protections against interested director transactions, conflicts of interest and ~~Financial~~similar ~~Disclosure~~matters and investors may be reluctant to provide us with funds necessary to expand our operations.

~~(a) On December~~The 8,costs ~~2015, RLB Certified Public Accountant PLLC ("RLB"), effective that date declined~~ to ~~stand~~meet ~~for~~our ~~reappointment~~reporting and to ~~act~~other requirements as ~~the~~a ~~Company’s independent registered~~ public ~~accountant.~~company Onsubject ~~December~~to ~~10, 2015, RLB was disallowed from practicing before~~ the ~~Commission.~~Exchange ~~During~~Act ~~the~~of ~~Company's~~1934 ~~fiscal~~is ~~year ended November 30, 2015,~~ and ~~the~~will ~~subsequent~~be ~~period~~substantial ~~through December 8, 2015, there were no disagreements between the Company~~ and ~~RLB~~may onresult ~~any~~in ~~matter~~us ~~of accounting principles or practices, financial statement~~having ~~disclosure,~~insufficient orfunds ~~auditing scope or procedure, which disagreements, if not resolved~~ to ~~RLB's~~expand ~~satisfaction,~~our ~~would~~business ~~have caused them to make reference to the subject matter of the disagreement in connection with their report on the Company's financial statements for such year~~ or ~~period;~~even and there were no reportable events as described in Item 304(a)(1)(v) of Regulation S-K. The Company has not provided RLB with a copy of the foregoing disclosures, since RLB cannot provide a response as it is no longer allowed to ~~practice~~meet ~~before~~routine ~~the~~business ~~Commission~~obligations.

OnAs ~~January~~a ~~27,~~public ~~2016~~entity, ~~Opulent~~subject ~~Acquisition,~~to ~~Inc. ("~~the ~~Company") engaged MaloneBailey, LLP~~reporting ~~("MaloneBailey")~~requirements of ~~Houston, TX, as its new registered independent public accountant. During~~ the ~~fiscal~~Exchange ~~year~~Act ~~ended~~of ~~November 30~~1934, ~~2015,~~ ~~and~~we ~~prior~~will continue to ~~January~~incur ~~27,~~ongoing ~~2016~~expenses ~~(the~~associated ~~date~~with ofprofessional ~~the~~fees ~~new~~for ~~engagement)~~accounting, ~~the Company did not consult with MaloneBailey regarding~~ ~~(i)~~legal ~~the~~and ~~application of accounting principles to~~ a ~~specified~~host ~~transaction, (ii) the type~~ of ~~audit~~other ~~opinion~~expenses ~~that~~for ~~might~~annual bereports ~~rendered on~~and ~~the~~proxy ~~Company's financial~~ statements. byWe ~~MaloneBailey,~~estimate inthat ~~either~~these ~~case~~costs ~~where~~will ~~written~~range orup ~~oral advice provided by MaloneBailey would be an important factor considered by us in reaching a decision as~~ to ~~any accounting~~$35,000 per ~~auditing~~year orfor ~~financial~~the ~~reporting~~next ~~issues~~few ~~or (iii)~~years ~~any~~and ~~other~~will ~~matter~~be ~~that~~higher ~~was~~if ~~the~~our ~~subject~~business ofvolume ~~a disagreement between us~~ and ~~our~~activity ~~former~~increases. ~~auditor~~As ora ~~was~~result, awe ~~reportable~~may ~~event~~not ~~(as~~have ~~described~~sufficient infunds ~~Items~~to ~~304(a)(1)(iv)~~grow orour ~~Item 304(a)(1)(v) of Regulation S-K, respectively)~~operations.

OnState ~~January~~Securities ~~27,~~Laws ~~2016,~~may ~~the~~limit ~~Company engaged MaloneBailey to audit the financial statements of the~~secondary ~~Company~~trading, which ~~comprise~~may ~~the~~restrict ~~balance sheets as of November 30, 2015 and November 30, 2014, and~~ the ~~related~~states ~~statements of operations, changes~~ in ~~stockholders’~~which ~~equity (deficit),~~ and ~~cash~~conditions ~~flows~~under for the year ended November 30, 2015 and the period from inception November 25, 2014 through November 30, 2014, and the related notes to the financial statements and schedules supporting the financial statements, all of which ~~are~~you tocan besell ~~included in the annual report (Form 10-K) proposed to be filed by the Company under the Securities Exchange Act of 1934~~Shares.

~~Item~~Secondary trading in our common stock 9Amay not be possible in any state until the common stock is qualified for sale under the applicable securities laws of the state or there is confirmation that an exemption, such as listing in certain recognized securities manuals, is available for secondary trading in the state. ~~Controls~~If ~~and~~we ~~Procedures~~fail to register or qualify, or to obtain or verify an exemption for the secondary trading of, the common stock in any particular state, the common stock cannot be offered or sold to, or purchased by, a resident of that state. In the event that a significant number of states refuse to permit secondary trading in our common stock, the liquidity for the common stock could be significantly impacted.

~~Disclosure Controls and Procedures~~-8-

~~The Company~~Table has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this annual report, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management, including the Chief Executive Officer who also serves as our Principal Financial Officer, has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Office who also serves as our Principal Financial Officer concluded that the disclosure controls and procedures are ineffective.Contents

~~The matters~~Item involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: domination of management by a single individual without adequate compensating controls, lack of a majority of outside directors on board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; inadequate segregation of duties consistent with control objectives, and lack of an audit committee1B. ~~These~~ ~~material~~Unresolved ~~weaknesses~~Staff ~~were identified by our Chief Executive Officer who also serves as our Chief Financial Officer in connection with the above annual evaluation~~Comments.

~~Management believes that the material weaknesses did not have an effect on our financial results~~None. However, management believes that the lack of a functioning audit committee and inadequate segregation of duties results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

~~Management recognizes~~Item ~~that~~2. ~~its controls and procedures would be substantially improved if we had an audit committee and two individuals serving as officers and as such is actively seeking to remediate this issue~~Properties.

~~Management’s~~Our ~~Report~~office space is located at 3901 NW 28th Street, 2nd Floor, Miami, FL 33142 . This space is provided to the Company rent free by Noel Mijares, who leases the office space on ~~Internal~~his ~~Control~~personal ~~over~~behalf. ~~Financial~~Besides ~~Reporting~~the aforementioned we do not have any other facilities or properties at which we operate. We believe this space is suitable to carry out current and future operations.

~~The Company’s~~Item ~~management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f)~~3. ~~The~~ ~~Company’s~~Legal internal control over financial reporting is designed to provide reasonable assurance to the Company’s management and board of directors regarding the preparation and fair presentation of published financial statementsProceedings. Management conducted an assessment of the Company’s internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control – Integrated Framework. Based on the assessment, management concluded that, as of November 30, 2015, the Company’s internal control over financial reporting is ineffective based on those criteria.

~~The Company’s~~From ~~management,~~time ~~including~~to ~~its Chief Executive Officer who also serves as our Chief Financial Officer~~time, ~~does~~we ~~not~~may ~~expect that~~become ~~the~~party ~~Company’s~~to ~~disclosure controls and procedures and its internal control processes will prevent all error and all~~litigation ~~fraud. A~~or ~~control~~other ~~system,~~legal noproceedings ~~matter how well conceived and operated, can provide only reasonable, not absolute, assurance~~ that ~~the~~we ~~objectives~~consider ofto ~~the~~be ~~control system are met. Further, the design of~~ a ~~control~~part ~~system must reflect the fact that there are resource constraints, and the benefits~~ of ~~controls must be considered relative to their costs. Because of~~ the ~~inherent limitations~~ordinary incourse ~~all control systems, no evaluation~~ of ~~controls~~our ~~can provide absolute assurance that all control issues and instances of error or fraud, if any, within the Company have been detected~~business. ~~These~~ ~~inherent~~We ~~limitations~~are ~~include~~not ~~the~~currently ~~realities that~~involved ~~judgments~~ in ~~decision-making~~legal ~~can~~proceedings ~~be faulty, and~~ that ~~the~~could ~~breakdowns~~reasonably ~~can occur because of simple error or mistake. Additionally, controls can~~ be ~~circumvented~~expected byto ~~the~~have ~~individual~~a ~~acts~~material ofadverse ~~some~~effect ~~persons,~~on byour ~~collusion of two or more people~~business, ~~or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events~~prospects, ~~and there can be no assurance that any design will succeed in achieving its stated goals under all potential~~financial ~~future~~condition ~~conditions. Over time, controls may become inadequate because of changes in conditions,~~ or ~~the~~results ~~degree~~ of ~~compliance with the policies or procedures may deteriorate~~operations. ~~Because~~ of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

~~Management’s Remediation~~Item ~~Initiatives~~4. Mine Safety Disclosures.

~~In an~~Not ~~effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:~~applicable.

~~We will~~PART create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. And, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.II

~~We will~~Market ~~work as quickly as possible to implement these initiatives; however, the lack of adequate working capital and positive cash flow from operations will likely slow this implementation.~~Information

~~Changes~~We are not currently listed on any exchange however, in ~~Internal~~the ~~Control~~future we intend to list on the OTC Marketplace.

There have been no changes in internal controls over the financial reporting that occurred during the period ending November 30, 2015, that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.Holders

~~This annual~~As ~~report does not include an attestation report~~ of ~~the~~November ~~Company’s~~30, ~~registered~~2016, ~~public~~there ~~accounting~~are ~~firm regarding internal~~approximately ~~control~~two ~~over~~(2) ~~financial~~shareholders ~~reporting. Management’s~~of ~~report~~record ~~was~~of ~~not~~our ~~subject~~common tostock ~~attestation~~and by1,000,000 ~~the~~shares ~~Company’s registered public accounting firm pursuant to temporary rules~~ of ~~the~~common ~~SEC~~stock ~~that~~deemed ~~permit~~issued ~~the~~and ~~Company to provide only management’s report in this annual report~~outstanding.

~~Item~~During the months of January, February and part of 9BMarch, the Company has sold 77,000 shares of common stock to a total of 26 new investors. ~~Other~~The ~~Information~~shares were sold pursuant to the Company’s effective S-1 Registration Statement deemed effective on December 7, 2016. The total proceeds from the sale of the aforementioned shares of common stock is/was $19,250. The proceeds are to be used for general working capital, Marketing & Advertising, and development of the Company’s website. As of the date of this report, March 14, 2017 we now have 28 shareholders of record.

~~None.~~Dividends and Share Repurchases

~~-8-~~We have not paid any dividends to our shareholder. There are no restrictions which would limit our ability to pay dividends on common equity or that are likely to do so in the future.

~~Table~~Issuer Purchases of ~~Contents~~Equity Securities

~~PART III~~None.

~~Item 10.~~Equity ~~Directors,~~Compensation ~~Executive~~Plan ~~Officers and Corporate Governance.~~Information

~~Noel Mijares,~~Not ~~Age 42 Chairman of the Board of Directors, Chief Executive Officer, and President~~applicable.

~~Background of~~Recent ~~Mr.~~Sales ~~Noel~~of ~~Mijares~~ Unregistered Securities

~~Noel Mijares~~Not ~~has extensive business experience and has amassed a great deal of knowledge over the years through his executive roles with a wide array of companies~~applicable. In 1992 Mijares formed Global Traders and became an authorized dealer for NCR. Mr. Mijares held the position of both President and CEO at Global Traders. Several years later in 1995 Mr. Mijares founded Safe Wrap of America, an international baggage wrap security company operating in nine countries at which he served as the Company’s President and CEO. Subsequently, in 2001 Mr. Mijares saw an opportunity to revolutionize legal resources for professionals and he founded The Subpoena Company of which became a formidable legal vendor amongst attorneys and publicly-traded insurance companies, nationwide. In 2009 Mr. Mijares expanded his reach with the legal sector and formed Unisource Discovery, Inc., a digital records retrieval, eDiscovery company and became a thought leader and well-published author in this area. More recently in 2015 Mr. Mijares was the CEO of Millennium Healthcare. From 2015 to present he has served as the Chairman, CEO, and President of iHealthcare, Inc.

~~Recent Experience:~~-9-

~~iHealthcare,~~Table ~~Inc. Chairman, CEO,~~of ~~President 2015-Present~~Contents

~~Pharma~~Item ~~Health Corp~~6. ~~Chairman,~~ Selected ~~CEO,~~Financial ~~President 2014-Present~~Data.

~~Unisource Discovery President,~~Consolidated ~~CEO 2009-Present~~Balance Sheets

The Subpoena Co. President, CEO 2001-Present

		As of November 30, 2016			As of November 30, 2015
ASSETS
Current Assets
Cash	$	33		$	-
Inventory		285			-
Total current assets	$	318		$	-
TOTAL ASSETS	$	318		$	-

LIABILITIES & STOCKHOLDERS’ DEFICIT
Current Liabilities

Accrued expenses	$	4,629		$	3,446
Due to related party		13,855			-
Total Current Liabilities		18,484			3,446

TOTAL LIABILITIES		18,484			3,446

Stockholders’ Deficit
Series A Preferred stock ($.0001 par value, 1,500,000 shares authorized; none issued and outstanding)		-			-
Series B Preferred stock ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding)		-			-
Common stock ($.0001 par value 143,500,000 shares authorized and 1,000,000 outstanding as of November 30, 2016 and November 30, 2015)		100			100
Subscription receivable		(5,500)			-
Additional paid in capital		43,598			8,118
Accumulated deficit		(56,364	)		(11,664)

Total Stockholders’ Deficit		(18,166)			(3,446)

TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$	318		$	-

~~Millennium~~Consolidated ~~Healthcare~~Statement ~~CEO 2015~~of Operations

Education:

		For the Year Ended November 30, 2016		For the Year Ended November 30, 2015

Revenues	$	1,428	$	-
Cost of Goods Sold		285		-
Gross profit		1,143
Operating Expenses
Organization and Related Expenses	$	3,118	$	646
Professional fees		42,725		6,850
Total operating expenses		45,843		7,496
Net loss	$	(44,700)	$	(7,496)
Basic and Diluted net loss per common share	$	(0.04)	$	(0.01)

Weighted average number of common shares outstanding - Basic and Diluted		1,000,000		1,000,000

~~- Miami~~Item ~~Dade~~7. ~~College~~Management’s ~~1992~~ Discussion and Analysis of Financial Condition and Results of Operations.

~~Publications~~Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

~~- Automating~~Liquidity ~~Document~~and ~~Retrieval~~Capital ~~– ALA Link: http://www.slideshare.net/NoelMijares/automatingdocumentretrievalala~~ Resources

-Our cash balance is $33 as of November 30, 2016. Our cash balance ~~Records~~is ~~Tracking~~not ~~and~~sufficient ~~Congestion~~to –fund ~~ALA~~our ~~Link:~~limited ~~http://www~~levels of operations for any period of time.~~slideshare.net/NoelMijares/records-tracking-~~ We have been utilizing and~~-congestion-ala~~ may utilize funds from Officers and Directors who have informally agreed to advance funds to allow us to pay for operating fees, and professional fees.

~~David A.~~If ~~Bingaman,~~we ~~Age~~need ~~60,~~additional ~~Chief~~cash ~~Operating~~and ~~Officer~~cannot raise it, ~~Vice~~we ~~President~~will either have to suspend operations until we do raise the cash we need, ~~and~~or ~~Secretary~~cease operations entirely.

~~Background of Mr. David Bingaman~~ Revenue

~~Mr. Bingaman~~For ~~has~~the ~~over~~year 30ended ~~years’~~November ~~experience~~30, in2016 the ~~healthcare~~Company ~~and software industry. He~~ has ~~served 15 years in senior executive~~generated Crevenue ~~- level roles~~ in ~~both private and public companies. With~~ the ~~publicly~~amount ~~traded~~of ~~American Medical Response~~$1, Mr428. ~~Bingaman~~The ~~led AMRs highest performing business unit from $36 million to $125 million in~~ revenue inwas ~~just~~the 4result ~~years~~of assales ~~regional~~of ~~CEO~~the ~~and~~“UDT ~~Senior~~Drug ~~Corporate Vice~~Screening ~~President~~Cup.” ~~Promoted~~For tothe ~~Senior Vice President for National Operations, he led a $1.3 Billion mission critical medical services~~year ~~business~~ended ~~with~~November ~~operations in 44 states~~30, ~~250~~2015 ~~sites~~the ~~and~~Company ~~22,000~~had ~~employees~~generated ~~then~~no ~~conducted 4 years of successful turnarounds and roll outs of major technology and business process improvement initiatives producing a net profit swing of approximately $37 million~~revenue. He ~~also~~The ~~met~~increase ~~and exceeded all financial targets~~ in ~~nearly 20 consecutive quarters through organic and acquisition growth. Mr. Bingaman secured $1.05 billion career medical business development~~ revenue ~~from multi-year high performance service contracts [SLAs] of $1-$25 million in commercial and government sectors. More recently, he led strategy and business plan development~~ for a ~~national~~the ~~physician~~year ~~medical~~ended ~~billing~~November ~~roll up~~30, ~~lead~~2016 ~~executive in seven SaaS ventures and five Blue Ocean strategy projects and~~was ~~developed~~due ato ~~mobile integrated health model. Mr. Bingaman holds a BA 2008 and MBA 2010 from The Corllins University and is graduate of~~ the ~~Valley~~fact ~~Medical~~that ~~Center School of Medicine’s Paramedicine Program 1976. Most recently he has served an executive position at~~ the ~~positions~~Company ~~listed~~began ~~below of which he continues~~ to ~~serve~~offer asthe ~~COO,~~“UDT ~~EVP,~~Drug ~~and~~Screening ~~Secretary~~Cup” offor ~~iHealthcare, Inc~~sale.

~~Recent Experience:~~Net Loss

~~2010~~We recorded a net loss of $44,700 for the year ended November -30, ~~2014:~~2016 ~~President:~~as ~~Aspen~~opposed ~~Ventures~~to $7,496 for the year ended November 30, 2015. The increase in net loss is attributed to increased operating expenses now that the business is operating at a higher level and thus has more expenses to pay for.

~~2014~~Going ~~- 2015: Chief Operating Officer: East Coast Ambulance LLC.~~Concern

~~2015~~For the year ended November 30, 2016, the Company has suffered recurring losses and had generated negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s management plans to engage in very limited activities without incurring any liabilities that must be satisfied in cash until a source of funding is secured. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue- ~~2015:~~producing ~~President:~~contracts ~~Millennium~~or ~~Healthcare~~financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, ~~Inc~~it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. These conditions and uncertainties raise substantial doubt as to the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

~~2015 -~~Current ~~Present:~~and ~~Chief~~Future ~~Operating~~Operations ~~Officer, EVP, Secretary: iHealthcare, Inc.~~Summarized

~~Employees~~At present our primary business activities consist of, and revolve around, the sale of the UDT Cup which is a urinalysis device used for drug screening. Our sale of the UDT Cup has resulted in our current sole revenue stream. We will continue to pursue the sale of the UDT Cup as our primary business objective. In addition to our principal business activities we, and our subsidiary iHealthcare Surgical LLC, have entered into various business agreements with third party entities as disclosed in our business plan herein. Although we have yet to achieve any revenue from these activities we are attempting to diversify our revenue streams by acting as a sales agent for entities in the healthcare industry, and to pursue potential joint ventures.

~~At November~~Item ~~30,~~7A. ~~2015~~Quantitative weand ~~had no~~Qualitative ~~employees~~Disclosures about Market Risk.

~~Directors’~~As a “smaller reporting company”, ~~Term~~we ofare ~~Office~~not required to provide the information required by this Item.

Directors will hold office until the next annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by our board of directors and serve at the discretion of the board of directors. Presently, we have a single director, Noel Mijares.-10-

~~Director Independence~~Table of Contents

~~Although our~~Item ~~securities do not trade on any national securities exchange, for purposes of independence we use the NASDAQ definition of independence~~8. ~~Our~~Financial ~~director,~~Statements ~~Noel~~and ~~Mijares,~~Supplementary ~~is not independent because of his position as an executive officer of the Company~~Data.

~~Audit Committee~~IHEALTHCARE, ~~and~~INC., ~~Audit Committee Financial Expert~~Inc.

~~Our~~FINANCIAL sole director acts as our audit committee and compensation committee. We do not have an “audit committee financial expert,” as that term is defined in Item 407(d) of Regulation S-K promulgated under the Securities Act. The sole director believes that he is financially literate and experienced in business matters and are capable of (1) understanding generally accepted accounting principles (“GAAP”) and financial statements, (2) assessing the general application of GAAP principles in connection with our accounting for estimates, accruals and reserves, (3) analyzing and evaluating our financial statements, (4) understanding internal controls and procedures for financial reporting, and (5) understanding audit committee functions, all of which are attributes of an audit committee financial expert. However, the sole director believes that no audit committee member has obtained these attributes through the experience specified in the SEC's definition of “audit committee financial expert.” Further, as is the case with many small companies, it would be difficult for us to attract and retain board members who qualify as “audit committee financial experts,” and competition for such individuals is significant. The sole director believes that its current audit committee is able to fulfill its role under SEC regulations despite not having a designated “audit committee financial expert.”STATEMENTS

~~Section~~INDEX ~~16(a)~~TO ~~Beneficial~~FINANCIAL ~~Ownership Reporting Compliance~~STATEMENTS

Section 16(a) of the Exchange Act requires the Company’s executive officers, directors and persons who beneficially own more than ten percent of a registered class of the Company’s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of the Company’s common stock. Such officers, directors and persons are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms that they file with the SEC.

		Pages

Report of Independent Registered Public Accounting Firm		F2

Consolidated Balance Sheets		F3

Consolidated Statements of Operations		F4

Consolidated Statements of Stockholders’ Deficit		F5

Consolidated Statements of Cash Flows		F6

Notes to Consolidated Financial Statements		F7-F8

Based solely on a review of the copies of such forms that were received by the Company, or written representations from certain reporting persons that no Form 5s were required for those persons, the Company is not aware of any failures to file reports or report transactions in a timely manner during the Company’s fiscal year ended November 30, 2015.-F1-

~~Code~~ Table of ~~Ethics~~Contents

~~We have~~REPORT ~~not~~OF ~~established~~INDEPENDENT aREGISTERED ~~Code~~PUBLIC ~~of Ethics applicable to our officers and directors.~~ACCOUNTING FIRM

~~Procedure for~~To ~~Nominating~~the Board of Directors and Stockholder of

~~In 2015~~iHealhcare, weInc ~~have~~( ~~not~~Formerly ~~made~~known ~~any~~as ~~material~~Opulent ~~changes to the procedures by which security holders may recommend nominees to our Board of~~Acquisitions, ~~Directors~~Inc.)

~~Family Relationships~~Miami, Florida

~~There~~We have audited the accompanying consolidated ~~are~~balance nosheets ~~family~~of ~~relationships~~iHealhcare, ~~among~~Inc. ~~our~~(formerly ~~directors~~known as Opulent Acquisitions, ~~executive~~Inc.) ~~officers~~(the or"Company") ~~persons~~as ~~nominated~~of November 30, 2016 and 2015 and the related consolidated statements of operations, changes in stockholders’ deficit and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to ~~become~~express ~~executive~~an ~~officers~~opinion oron ~~directors~~these consolidated financial statements based on our audits.

~~Involvement~~We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in ~~Certain~~the ~~Legal~~circumstances, ~~Proceedings~~but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

~~During~~ In our opinion, the ~~past~~consolidated ~~ten~~financial statements ~~(10)~~referred ~~years~~to above present fairly, ~~none~~in ofall ~~our~~material ~~directors~~respects, ~~persons~~the ~~nominated~~financial toposition ~~become~~of ~~directors,~~the ~~executive officers~~Company, ~~promoters~~as orof ~~control~~November 30, ~~persons~~2016 ~~was~~and ~~involved~~2015 inand ~~any~~the results of their operations and their cash flows for the ~~legal~~years ~~proceedings~~then ~~listen~~ended in ~~Item~~conformity ~~401~~with ~~(f)~~accounting ofprinciples generally ~~Regulation~~accepted ~~S-K~~in the United States of America.

~~Arrangements~~The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the Company has suffered a net loss, working capital deficiency, has minimal asset, nor does it have a significant source of revenue sufficient to cover its operation which raises substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters also are described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~There are~~/s/ ~~no arrangements or understandings between an executive officer~~MaloneBailey, ~~director or nominee and any other person pursuant to which he was or is to be selected as an executive officer or director.~~LLP

~~-9-~~www.malonebailey.com

~~Table~~Houston, ~~of Contents~~Texas

~~Item 11.~~March ~~Executive~~13, ~~Compensation.~~2017

The table below summarizes all compensation awarded to, earned by, or paid to our named executive officer for all services rendered in all capacities to us for the years ended November 30, 2015 and 2014.-F2-

SUMMARY COMPENSATION TABLE
Name and principal position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Noel Mijares Chief Executive Officer Chief Financial Officer Noel Mijares Chief Executive Officer Chief Financial Officer	2015 2014	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0 0
Jeffrey DeNunzio, Former Chief Executive Officer Chief Financial Officer Jeffrey DeNunzio, Former Chief Executive Officer Chief Financial Officer	2015 2014	0 0	0 0	2,000 2,000	0 0	0 0	0 0	0 0	2,000 2,000

Table of Contents

~~On January 14~~IHEALTHCARE, ~~2016 Mr~~INC. Jeffrey DeNunzio transferred to iHealthcare, Inc., 20,000,000 shares of our common stock which represents all of our issued and outstanding shares. Noel Mijares and David A. Bingaman are the controlling shareholders of iHealthcare, Inc., a Florida corporation. Mr.Mijares owns 62.5% and Mr. Bingaman owns 37.5% of the issued and outstanding shares of iHealthcare, Inc.

~~On January~~(FORMERLY ~~14,~~KNOWN ~~2016,~~AS ~~Mr.~~OPULENT ~~Jeffrey DeNunzio resigned as Chief Executive Officer~~ACQUISITION, ~~Chief Financial Officer, President, Secretary, Treasurer~~ ~~and Director~~INC.)

~~On January~~CONSOLIDATED ~~14,~~BALANCE ~~2016, Mr. Noel Mijares was appointed as Chairman of the Board of Directors, Chief Executive Officer, and President.~~SHEETS

On January 14, 2016, Mr. David A. Bingaman was appointed as Chief Operating Officer, Vice President, and Secretary.

		As of November 30, 2016			As of November 30, 2015
ASSETS
Current Assets
Cash	$	33		$	-
Inventory		285			-
Total Current Assets	$	318		$	-
TOTAL ASSETS	$	318		$	-

LIABILITIES & STOCKHOLDERS’ DEFICIT
Current Liabilities

Accrued expenses	$	4,629		$	3,446
Due to related party		13,855			-
Total Current Liabilities		18,484			3,446

TOTAL LIABILITIES		18,484			3,446

Stockholders’ Deficit
Series A Preferred stock ($.0001 par value, 1,500,000 shares authorized; none issued and outstanding)		-			-
Series B Preferred stock ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding)		-			-
Common stock ($.0001 par value 143,500,000 shares authorized and 1,000,000 outstanding as of November 30, 2016 and November 30, 2015)		100			100
Subscription receivable		(5,500)			-
Additional paid in capital		43,598			8,118
Accumulated deficit		(56,364	)		(11,664)

Total Stockholders’ Deficit		(18,166)			(3,446)

TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$	318		$	-

~~Option/SAR Grants~~See inAccompanying ~~Last~~Notes ~~Fiscal~~to ~~Year~~the Consolidated Financial Statements.

~~None.~~-F3-

~~Outstanding Equity~~Table ~~Awards~~of ~~at Fiscal Year-End~~Contents

~~None~~IHEALTHCARE, INC.

~~Compensation of~~(FORMERLY ~~Directors~~KNOWN AS OPULENT ACQUISITION, INC.)

~~The Company’s~~CONSOLIDATED ~~sole~~STATEMENTS ~~director~~OF ~~received no compensation for services as director during the last fiscal year.~~OPERATIONS

Equity Compensation Plan Information

		For the Year Ended November 30, 2016		For the Year Ended November 30, 2015

Revenues	$	1,428	$	-
Cost of Goods Sold		285		-
Gross profit		1,143		-
Operation Expenses
Organization and Related Expenses		3,118		646
Professional fees		42,725		6,850
Total operating expenses		45,725		7,496
Net loss	$	(44,700)	$	(7,496)
Basic and Diluted net loss per common share	$	(0.04)	$	(0.01)

Weighted average number of common shares outstanding - Basic and Diluted		1,000,000		1,000,000

~~Not~~See Accompanying Notes to the Consolidated ~~applicable~~Financial Statements.

~~Employment Agreements~~-F4-

~~None.~~Table of Contents

~~Item~~IhEALTHCARE, 12iNC. ~~Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.~~

~~The following table sets forth certain information regarding beneficial ownership of our common stock and warrants to purchase shares of our common stock as of February 18, 2016 by~~ (~~i) each person (or group of affiliated persons) who is known by us to own more~~FORMERLY ~~than~~KNOWN ~~five~~AS ~~percent~~OPULENT ~~of the outstanding shares of our common stock~~ACQUISITION, ~~(ii) each of our directors and executive officers, and (iii) all of our directors and executive officers as a group~~INC. ~~As of February 18, 2016, there were 20,000,000 shares of common stock outstanding.~~)

~~Beneficial ownership~~CONSOLIDATED isSTATEMENTS ~~determined~~OF ~~in accordance with SEC rules and generally includes voting or investment power with respect to securities.~~CHANGES ~~The~~IN ~~principal~~STOCKHOLDERS’ address of each of the stockholders listed below is 141 NE 3rd Avenue, Miami, FL 33132. We believe that all persons named in the table have sole voting and investment power with respect to shares beneficially owned by them.DEFICIT

~~Principal~~FOR ~~Stockholders~~THE ~~Table~~YEARS ENDED NOVEMBER 30, 2015 and NOVEMBER 30, 2016

Name of Owner		Shares Owned			Percentage of Shares Outstanding
	Common Stock			Par Value Common Stock		Additional Paid-in Capital			Subscription Receivable		Accumulated Deficit		Total
iHealthcare, Inc. (1)			20.000,000			100	%
Balance November 30, 2014	1,000,000		$	100	$	1,920		$	-	$	(4,168)		(2,148)
Contributed Expenses	-			-		6,198			-		-		6,198
Net Loss	-			-		-			-		(7,496)		(7,496)
Balance November 30, 2015	1,000,000		$	100	$	8,118		$	-	$	(11,644)		(3,446)
Subscription receivable contributed in merger	-			-		34,980			(34,980)		-		-
Subscription receivable collected	-			-		-			21,980		-		21,980
Netting of subscription receivable against related party loan	-			-		-			7,500		-		7,500
Forgiveness of related party loan into converted capital	-			-		500			-		-		500
Net Loss	-			-		-			-		(44,700)		(44,700)
Balance November 30, 2016	1,000,000		$	100	$	43,598		$	(5,500)	$	(56,364)	$	(18,166)

~~(1)~~See ~~Mr.Mijares~~Accompanying ~~owns~~Notes ~~62.5%~~to ~~and Mr. Bingaman owns 37.5% of~~ the Consolidated ~~issued~~Financial ~~and outstanding shares of iHealthcare, Inc~~Statements.

-10F5-

Table of Contents

~~Item~~IHEALTHCARE, 13INC. ~~Certain Relationships and Related Transactions, and Director Independence.~~

~~Following~~(FORMERLY ~~our~~KNOWN ~~year~~AS ~~end~~OPULENT ~~November 30~~ACQUISITION, ~~2015 the following material events have occurred:~~INC.)

~~On January~~CONSOLIDATED ~~11,~~STATEMENTS ~~2016,~~OF ~~Jeffrey~~CASH DeNunzio of 780 Reservoir Avenue, #123, Cranston, RI 02910, the sole shareholder of Opulent Acquisition, Inc. (the “Registrant” or “Company”), entered into a Share Purchase Agreement (the “Agreement”) with iHealthcare, Inc., with an address at 141 NE 3rd Avenue, Miami, FL 33132.FLOWS

Pursuant to the Agreement, on January 14, 2016 Mr. Jeffrey DeNunzio transferred to iHealthcare, Inc., 20,000,000 shares of our common stock which represents all of our issued and outstanding shares. Noel Mijares and David A. Bingaman are the controlling shareholders of iHealthcare, Inc., a Florida corporation. Mr.Mijares owns 62.5% and Mr. Bingaman owns 37.5% of the issued and outstanding shares of iHealthcare, Inc.

		For the Year Ended November 30, 2016		For the Year Ended November 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(44,700)	$	(7,496)
Adjustment to reconcile net loss to net cash used in operating activities:
Expenses contributed to capital		-		6,198
Changes in current assets and liabilities:
Increase in inventory		(285)		-
Increase (decrease) in accrued expenses		20,728		1,298
Net cash used in operating activities	$	(24,257)	$	-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds received from related party loan		6,115		-
Payments made on related party loan		(3,805)		-
Collection of Subscription Receivable		21,980		-
Net cash provided by Financing Activities	$	24,290	$	-

Increase (Decrease) in cash		33		-
Beginning cash balance		-		-
Ending cash balance	$	33	$	-

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	$	-	$	-
Income taxes paid	$	-	$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES
Netting of subscription receivable against related party loan	$	7,500	$	-
Subscription receivable contributed in merger	$	34,980	$	-
Due to related party for expenses paid on behalf of the Company	$	19,545	$	-
Forgiveness of related party loan into converted capital	$	500	$	-

~~On January~~See ~~14,~~Accompanying ~~2016,~~Notes ~~Mr.~~to ~~Jeffrey~~the ~~DeNunzio resigned as Chief Executive Officer, Chief~~ Consolidated Financial ~~Officer, President, Secretary, Treasurer and Director~~Statements.

~~On January 14, 2016, Mr. Noel Mijares was appointed as Chairman of the Board of Directors, Chief Executive Officer, and President.~~-F6-

~~On January~~Table ~~14,~~of ~~2016, Mr. David A. Bingaman was appointed as Chief Operating Officer, Vice President, and Secretary.~~Contents

~~Item~~IHEALTHCARE, 14INC. ~~Principal Accounting Fees and Services.~~

~~Below~~(FORMERLY isKNOWN ~~the~~AS ~~aggregate~~OPULENT ~~amount~~ACQUISITION, ~~of fees billed for professional services rendered by our principal accountants with respect to our last two fiscal years~~INC.)

		2015	2014
Audit fees	MaloneBailey, LLP	$3,750	$0
Audit related fees		-	-
Tax fees		-	-
All other fees		-	-
Total		$3,750	$0

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

~~Audit fees represent the professional~~NOVEMBER ~~services rendered for the audit of our annual financial statements and the review of our financial statements included in quarterly reports~~30, ~~along~~2016 ~~with services normally provided by the accounting firm in connection with statutory~~ and regulatory filings or engagements. Audit-related fees represent professional services rendered for assurance and related services by the accounting firm that are reasonably related to the performance of the audit or review of our financial statements that are not reported under audit fees.2015

~~Tax fees represent professional services rendered by the accounting firm for~~NOTE ~~tax~~1 ~~compliance,~~- ~~tax~~ORGANIZATION ~~advice,~~AND ~~and~~DESCRIPTION ~~tax~~OF ~~planning. All other fees represent fees billed for products and services provided by the accounting firm, other than the services reported for in the other categories.~~BUSINESS

~~-11-~~iHealthcare Inc. (formerly Opulent Acquisition, Inc.) (the Company) was incorporated under the laws of the State of Delaware on November 25, 2014. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business. The Company originally elected November 30th as its year end but has applied to change its fiscal year end to December 31. As of now however, the fiscal year is November 30th.

~~Table~~On January 14, 2016 Mr. Jeffrey DeNunzio, the sole shareholder of ~~Contents~~the Company transferred to iHealthcare, Inc., a Florida Company, 20,000,000 shares of our common stock which represented all of our issued and outstanding shares at the time of transfer, in consideration of $25,000. The transfer was the result of the sale of the Company to iHealthcare, Inc., the Florida Company. The result of the January 14, 2016 transaction was iHealthcare, Inc. (formerly Opulent) became the wholly owned subsidiary of iHealthcare, Inc. (Florida). Due to management’s intent to merge iHealthcare, Inc. (formerly Opulent) and iHealthcare, Inc. (Florida) at a later date $34,980 paid by iHealthcare, Inc. (Florida) was accounted for in Paid in Capital of iHealthcare, Inc. (Florida). This was based on a conclusion that iHealthcare, Inc. (formerly Opulent) would not qualify as a business under ASC 805 due to iHealthcare, Inc.’s (formerly Opulent) lack of assets, operations, inputs or processes at the acquisition date. The use of Fair Value and purchase accounting did not appear appropriate considering the aforementioned facts and management’s intent to merge the entities. Management took a view at the acquisition date towards 805-50 and the eventual use of the rules covering a merger of entities under common control.

~~PART~~On January 14, 2016 iHealthcare, Inc., IVa Florida Company, became the controlling shareholder of Opulent Acquisition, Inc. At the time of the sale of Opulent Acquisition, Inc. Mr. Mijares owned 62.5% and Mr. Bingaman owned 37.5% of the issued and outstanding shares of iHealthcare, Inc., the Florida Company.

~~Item 15~~On January 14, 2016, Mr. ~~Exhibits~~Jeffrey DeNunzio resigned as Chief Executive Officer, Chief Financial ~~Statement~~Officer, ~~Schedules~~President, Secretary, Treasurer and Director of Opulent Acquisition, Inc.

~~(a)~~On January 14, 2016, Mr. Noel Mijares ~~Financial~~was ~~Statements~~appointed as Chairman of the Board of Directors, Chief Executive Officer, and President.

~~1. Financial~~On ~~statements~~January ~~for~~14, ~~our~~2016, ~~company~~Mr. ~~are~~David ~~listed~~A. inBingaman was ~~the~~appointed ~~index~~as ~~under~~Chief ~~Item~~Operating 8Officer, ofVice ~~this~~President, ~~document~~and Secretary.

2.On April 22, 2016 we, Opulent Acquisition, ~~All~~Inc. ~~financial~~(“iHealthcare, ~~statement~~Inc.-Delaware”) ~~schedules~~entered ~~are~~into ~~omitted~~and ~~because~~consummated ~~they~~a ~~are~~merger ~~not~~with ~~applicable~~iHealthcare, ~~not~~Inc., ~~material~~a orFlorida ~~the~~Company (“iHealthcare, ~~required~~Inc.-Florida”). ~~information~~iHealthcare, Inc.-Delaware is ~~shown in~~the Surviving Corporation as result of the ~~financial~~merger. ~~statements~~The officers orand ~~notes~~directors ~~thereto~~of Opulent Acquisition, Inc., now known as iHealthcare, Inc., remained the same and unchanged.

On April 22, 2016, iHealthcare, Inc. (bformerly Opulent) ~~Exhibits~~ ~~required~~and iHealthcare, Inc. (Florida) were under common control. iHealthcare, Inc. (formerly Opulent) was 100% owned by ~~Item~~iHealthcare, ~~601~~Inc. of(Florida). ~~Regulation~~Due Sto the parent subsidiary relationship on April 22, 2016, under ASC 805-K50, the transaction is being accounted for similar to a pooling of interests with carryover basis being used and go forward reporting will have the entities combined from the first day of the first period presented.

Exhibit No.		Description
3.1		Certificate of Incorporation (1)
3.2		By-laws. (1)
31.1		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-K for the year ended November 30, 2015. (2)
32.1		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
101.INS		XBRL Instance Document (3)
101.SCH		XBRL Taxonomy Extension Schema (3)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase (3)
101.DEF		XBRL Taxonomy Extension Definition Linkbase (3)
101.LAB		XBRL Taxonomy Extension Label Linkbase (3)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase (3)

On April 22, 2016, the Company filed with the Delaware Secretary of State an amendment to the Company’s certificate of incorporation, changing its name to iHealthcare, Inc.

~~____________________~~On May 13, 2016 David A. Bingaman was appointed as Chief Financial Officer, Chief Accounting Officer, and Director.

(1)	Filed as an exhibit to the Company's Registration Statement on Form 10, as filed with the SEC on February 19, 2015, and incorporated herein by this reference.
(2)	Filed herewith.
(3)	Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

On July 25, 2016 we, iHealthcare, Inc., organized iHealthcare Surgical, LLC, a Florida Limited Liability Company. The members of the LLC include iHealthcare, Inc., and All in 1 Medical, LLC. Each of the aforementioned parties own 50% of the membership interests in iHealthcare Surgical, LLC. All in 1 Medical, LLC is owned and operated by Mark Heffner, who is a non-affiliate of iHealthcare, Inc.

~~SIGNATURES~~As of November 30, 2016 Ihealthcare Surgical, LLC has not had any monetary transactions. Per the above the Company has applied ASC 323 for presentation and disclosure requirements. Because Ihealthcare Surgical, LLC conducted no monetary business as of November 30, 2016 there were no transactions recorded on the books for the year ended November 30, 2016..

~~Pursuant~~On August 19, 2016 Ihealthcare Surgical, LLC, entered into and consummated a joint venture agreement with All In 1 Medical, LLC. The purpose of the joint venture agreement is to forge a relationship that through means, which will be determined at a future date, will bring together both parties in an effort to sell, to be determined, medical products. Each party retains a 50% interest in the ~~requirements~~joint ofventure. ~~Section~~Each 13party orhas ~~15(d)~~also ofagreed to split profits and expenses equally that relate to the ~~Securities~~joint ~~Exchange~~venture. ~~Act~~The term of ~~1934~~the joint venture agreement is through August 4, 2026. It may be renewed for an additional five year term if agreed upon by both parties. Each party of the ~~registrant~~joint venture agreement has ~~duly~~agreed ~~caused~~to contribute $500 for business purposes set forth in the joint venture agreement. Neither party has, as of the date of this report , contributed the $500, however both parties intend to bemake ~~signed~~such oncontribution ~~its~~after ~~behalf~~a byjoint bank account is opened up for the ~~undersigned~~purpose of the joint venture. Under ASC 808 this does not apply since the entity, ~~thereunto~~is ~~duly~~setup ~~authorized~~as a wholly owned subsidiary and ASC 323 would not apply since there is no consideration paid as of the year end November 30, 2016.

~~Opulent~~On October 3, 2016 iHealthcare Surgical, ~~Acquisition~~LLC entered into and consummated an agreement with Precision Spine, Inc., “Precision,” to act as Precision’s sales agent in regards to the sale of spinal implants and other medical products that are manufactured for or by Precision. iHealthcare, Inc. is to receive a 40% commission on the sale of spinal implants for the fourth quarter of 2016 and effective January of 2017, 35%, +5% each quarter if iHealthcare is able to generate sales of $300,000 or more in a quarterly period. For “Biologic” products as they are categorized in the agreement, iHealthcare will receive a to be decided upon commission that is agreed upon by both parties at a later date. Regarding disposable single use instruments, iHealthcare, Inc. will receive a 20% commission for any sales generated on Precision’s behalf. On December 6, 2016 iHealthcare Surgical, LLC and Precision Spine, Inc. mutually agreed to the termination of the agreement entered into on October 3, 2016. There were no revenues generated under this agreement.

~~(Registrant)~~On October 10, 2016 our subsidiary, iHealthcare Surgical, LLC entered into an agreement with Gensano, LLC. Under the terms of the agreement iHealthcare Surgical, LLC will act as a sales agent for Gensano, LLC by attempting to sell products on their behalf. In this agreement iHealthcare Surgical, LLC will receive a sales commission which will be comprised of the difference between the price of Gensano’s products and the actual cost at which iHealthcare Surgical manages to sell the products. Gensano has set a fixed cost, per product, that they must receive from the sale of each item. IHealthcare Surgical, LLC will not directly purchase products from Gensano, and all shipping will be conducted directly from Gensano to the customer. There were no revenues generated under this agreement.

~~By:~~On November 25, 2016 iHealthcare Surgical, LLC entered into an ~~/s/~~agreement ~~Noel~~with ~~Mijares~~S1 Spine. Under the terms of the agreement S1 Spine has appointed iHealthcare Surgical, LLC to act as its sales agent to solicit orders for the products of S1 Spine. Sales are to be attempted, by iHealthcare Surgical LLC in Florida, Georgia, Nevada and New Mexico. In exchange for operating as the sales agent for S1 Spine, iHealtcahre Surgical shall receive a commission based upon the net invoice price of products offered for sale. There were no revenues generated under this agreement.

~~Noel~~NOTE ~~Mijares,~~2 ~~Chief~~- ~~Executive~~SUMMARY ~~Officer,~~OF ~~President,~~SIGNIFICANT ~~Chairman~~ACCOUNTING ~~of the Board of Directors~~POLICIES

~~Dated:~~Basis ~~February~~of ~~18, 2016~~Presentation

~~Pursuant~~The Financial Statements and related disclosures have been prepared pursuant to the ~~requirements~~rules and regulations of ~~Section~~the 13Securities and Exchange orCommission 15(d“SEC”). ofThe ~~the~~Financial ~~Securities~~Statements ~~Exchange~~have ~~Act~~been ofprepared ~~1934,~~using the ~~registrant~~accrual ~~has~~basis ~~duly~~of ~~caused~~accounting ~~this~~in ~~report~~accordance with toGenerally beAccepted ~~signed~~Accounting onPrinciples ~~its~~(“GAAP”) ~~behalf~~of bythe United States (See Note 3) regarding the ~~undersigned,~~assumption ~~thereunto~~that ~~duly~~the ~~authorized~~Company is a “going concern”.

~~Opulent Acquisition, Inc.~~Inventories

Inventories, consisting of products available for sale, are primarily accounted for using the first-in, first-out (~~Registrant~~"FIFO") method, and are valued at the lower of cost or market value. This valuation requires iHealthcare, Inc. to make judgments, based on currently-available information, about the likely method of disposition, such as through sales to individual customers, returns to product vendors, or liquidations, and expected recoverable values of each disposition category.

~~By:~~Revenue ~~/s/ David A. Bingaman~~Recognition

~~David~~The Company recognizes revenue Awhen it is realized or realizable and earned. ~~Bingaman~~The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, ~~Chief~~(ii) ~~Operating~~the ~~Officer~~product has been shipped or the services have been rendered to the customer, ~~Vice~~(iii) ~~President~~the sales price is fixed or determinable, ~~Secretary~~and (iv) collectability is reasonably assured.

~~Dated:~~PRINCIPALS ~~February~~OF ~~18, 2016~~CONSOLIDATION

~~-12-~~These financial statements include the accounts of the Company’s wholly owned subsidiary iHealthcare, all material intercompany balances and transactions have been eliminated.

USE OF ESTIMATES.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amount of revenues and expenses during the reporting period. Actual results could differ from these estimates. Due to the limited level of operations, the Company has not had to make material assumptions or estimates other than the assumption that the Company is a going concern.

FISCAL YEAR END.

The Company elected November 30th as its fiscal year ending date.

CASH AND CASH EQUIVALENTS.

For the purpose of the financial statements cash equivalents include all highly liquid investments with original maturity of three months or less.

COMMITMENTS AND CONTINGENCIES.

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it

is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

EARNINGS (LOSS) PER SHARE.

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during each period. There were no potentially dilutive shares outstanding as of November 30, 2016 and 2015.

FAIR VALUE OF FINANCIAL INSTRUMENTS.

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

INCOME TAXES.

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

RELATED PARTY TRANSACTIONS.

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

SHARE-BASED EXPENSE.

ASC 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

RECENTLY ISSUED ACCOUNTING- PRONOUNCEMENTS.

Management has considered all recent accounting pronouncements issued since the last audit of our financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's financial statements.

-F7-

Table of Contents

NOTE 3 - GOING CONCERN

The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

The Company demonstrates adverse conditions that raise substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, negative cash flow from operating activities, and other adverse key financial ratios.

The Company has not established any source of revenue to cover its operating costs. Management plans to fund operating expenses with related party contributions to capital. There is no assurance that management's plan will be successful.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

NOTE 4 - RELATED-PARTY TRANSACTIONS

Forgiveness of Loans

Pharma Tropical, which is controlled by our Chief Executive Officer, loaned the Company $500 during the year for payment of Company expenses which was considered forgiven and converted to contributed capital as an addition to additional paid in capital.

Due to related party

Unisource Discovery, Inc., is a related party and is controlled by our Chief Executive Officer, Noel Mijares. During the year ending November 30, 2016 Unisource Discovery Inc. advanced the Company $6,115 and the Company made payment of $3,805 on these advances. The total due to the Unisource Discovery Inc. as November 30, 2016 is $2,310 which is noninterest bearing, unsecured, and due on demand

During the year ending November 30, 2016, the Company borrowed $19,545 from its CEO to pay for expenses on behalf of the company in the current year and $7,500 of these payments were posted as a reduction to subscription receivable. As of November 30, 2016, the Company was indebted to the Chief Executive Officer of the Company in the amount of $11,545, which is noninterest bearing, unsecured, and due on demand.

Additional paid in capital

As a result of the merger a subscription receivable was contributed by the principal shareholders in the amount $34,980. The Company has collected $21,980 from the subscription receivable and converted advances of $7,500 due to the Company’s CEO and the balance as of November 30, 2016 is $5,500.

Office Space

Our office space is located at 3901 NW 28th Street, 2nd Floor, Miami, FL 33142 . This space is provided to the Company rent free by Noel Mijares, who leases the office space on his personal behalf.

Expenses Contributed to Capital

We had expenses contributed to capital of $6,198 for the Year Ended November 30, 2015 from the Company’s former officer.

NOTE 5 - EQUITY

Previous to the Merger Noel Mijares owned 6,250 shares of common stock of iHealthcare, Inc., the Florida Company and David A Bingaman owned 3,750 shares of common stock of iHealthcare, Inc., the Florida Company. After the merger each one of these shares were converted into 100 shares of our common stock (iHealthcare, Inc., a Delaware Company, formerly known as Opulent Acquisition, Inc). The 20,000,000 shares of common stock owned by iHealthcare, Inc., a Florida Company of iHealthcare, Inc., formerly known as Opulent Acquisition Inc., a Delaware Company were cancelled upon consummation of the merger. All share amounts are adjusted retroactively.

Currently, Noel Mijares owns 625,000 shares of our common stock and David A Bingaman owns 375,000 shares of our common stock.

The total number of authorized shares of stock that the Company is authorized to issue is 150,000,000, consisting of 143,500,000 shares of Common Stock, $0.0001 par value per share, and 6,500,000 shares of Preferred Stock, $0.0001 par value per share.

We had expenses contributed to capital of $6,198 for the Year Ended November 30, 2015 from the Company's former officer.

NOTE 6 - INCOME TAXES

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the periods presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. Section 382 of the Internal Revenue Code generally requires us to limit the amount of its income in future years that can be offset by historic losses, i.e. net operating loss (NOL) carryforwards and certain built-in losses, after a corporation has undergone an ownership change. As of November 30, 2016, the Company has incurred net carryfoward losses of $(56,344) resulting in a net operating loss for income tax purposes. NOLs begin expiring in 2035. The loss results in a deferred tax asset of approximately $19,720 at the effective statutory rate of 35%. The deferred tax asset has been off-set by an equal valuation allowance.

	November 30,

	2016		2015
Deferred tax asset, generated from net operating loss at statutory rates	$	19,720	$	4,075
Valuation allowance		(19,720 )		(4,075)
	$	—	$	—

The reconciliation of the effective income tax rate to the federal statutory rate is as follows:

Federal income tax rate	35.0	%
Increase in valuation allowance	(35.0	%)
Effective income tax rate	0.0	%

NOTE 7 - SUBSEQUENT EVENTS

Subsequent to November 30, 2016, the Company sold 77,000 common shares at $0.25 per share for proceeds of $19,250 in cash.

Subsequent to November 30, 2016, the company has received $650 and made payments of $4,351 on a loan from a company controlled by the CEO. The Company has recorded $6,972 in loan from CEO for cash contributed and payment of expenses on behalf of the Company by the CEO. The loans are noninterest bearing, unsecured, and due on demand.

On February 23, 2017 Ihealthcare, Inc. entered into an agreement with John Cook and Paul Pereira. Under the terms of the agreement John Cook and Paul Pereira will act as part time consultants for Ihealthcare, Inc. Their role shall pertain to assisting the Company with obtaining and structuring institutional financing from various commercial banks, investment banking firms, private equity firms and related financial and business issues. John Cook and Paul Pereira shall be compensated for their part time assistance as consultants through a combination of cash and stock incentives. John Cook and Paul Pereira shall be awarded a total of 10.00%, respectively, of Series B Preferred stock based upon acquisition milestones. The 10.00% to that point shall be Series B Preferred Stock, however, if they assist the Company in achieving gross revenues exceeding $200,000,000 then they will each be awarded an extra 2.5% of the Preferred Stock in a new class with the same rights as Series B. This would bring their total equity interest to 12.50% each, and 25.00% total.

-F8-

Table of Contents

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None

Item 9A. Controls and Procedures.

Disclosure Controls and Procedures

The Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this report, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are ineffective due the material weaknesses identified below.

Management’s Report on Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f). The Company’s internal control over financial reporting is designed to provide reasonable assurance to the Company’s management and board of directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of the Company’s internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control – Integrated Framework. Based on the assessment, management concluded that, as of November 30, 2016, the Company’s internal control over financial reporting is ineffective based on those criteria.

The matters involving internal controls and procedures that our management considered to be material weaknesses: domination of management by a limited individuals without adequate compensating controls, lack of a majority of outside directors on board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; inadequate segregation of duties consistent with control objectives, lack of well-established procedures to identify, approve and report related party transactions, and lack of an audit committee. These material weaknesses were identified by our Chief Executive Officer and Chief Financial Officer in connection with the above annual evaluation.

Management believes that the material weaknesses did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and inadequate segregation of duties results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Management recognizes that its controls and procedures would be substantially improved if we had an audit committee and two individuals serving as officers and as such is actively seeking to remediate this issue.

The Company’s management does not expect that the Company’s disclosure controls and procedures and its internal control processes will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of error or fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that the breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

Management’s Remediation Initiatives

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures:

We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. And, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us.

Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board.

We will work as quickly as possible to implement these initiatives; however, the lack of adequate working capital and positive cash flow from operations will likely slow this implementation.

Changes in Internal Control

There have been no changes in internal controls over the financial reporting that occurred during the fiscal fourth quarter, that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

This report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

Item 9B. Other Information.

None.

-11-

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Biographical information regarding the Officers and Directors of the Company, who will continue to serve as Officers and Directors of the Company are provided below:

Ihealthcare, Inc.

NAME		AGE				POSITION
Noel Mijares			42				Chief Executive Officer, President, Chairman of the Board of Directors

NAME		AGE				POSITION
David A. Bingaman			60				Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Vice President, Secretary, Director

Noel Mijares, Age 42 Chairman of the Board of Directors, Chief Executive Officer, and President

Background of Mr. Noel Mijares

Noel Mijares has extensive business experience and has amassed a great deal of knowledge over the years through his executive roles with a wide array of companies. In 1992 Mijares formed Global Traders and became an authorized dealer for NCR. Mr. Mijares held the position of both President and CEO at Global Traders until 2000. Several years later in 1995 Mr. Mijares founded Safe Wrap of America, an international baggage wrap security company operating in nine countries at which he served as the Company’s President and CEO from 1996 until 2000. Subsequently, in 2001 Mr. Mijares saw an opportunity to revolutionize legal resources for professionals and he founded The Subpoena Company of which became a formidable legal vendor amongst attorneys and publicly-traded insurance companies, nationwide. In 2009 Mr. Mijares expanded his reach with the legal sector and formed Unisource Discovery, Inc., a digital records retrieval, eDiscovery company and became a thought leader and well-published author in this area. More recently in 2015 Mr. Mijares was the CEO of Millennium Healthcare. From 2015 to April 2016 he has served as the Chairman, CEO, and President of Ihealthcare, Inc., a Florida Corporation of which has merged with and into the Company.

Recent Experience:

Ihealthcare, Inc. (Florida Corporation) Chairman, CEO, President 2015 - April 2016

Pharma Health Corp. Chairman, Pharmaceuticals, CEO, President 2014-Present

Unisource Discovery, Digital Document Retrieval, President, CEO 2009-Present

The Subpoena Co., Legal and Litigation Support Vendor, President, CEO 2001-Present

Millennium Healthcare CEO 2015

Education:

- Miami Dade College 1992

Publications:

- Automating Document Retrieval – ALA Link: http://www.slideshare.net/NoelMijares/automatingdocumentretrievalala

- Records Tracking and Congestion – ALA Link: http://www.slideshare.net/NoelMijares/records-tracking-and-congestion-ala

David A. Bingaman, Age 60, Chief Operating Officer, Vice President, and Secretary, Director

Background of Mr. David Bingaman

Mr. Bingaman has over 30 years’ experience in the healthcare and software industry. He has served 15 years in senior executive C - level roles in both private and public companies. Mr. Bingaman joined American Medical Response as Executive Vice President and Chief Operating Officer, a position he held from 1992 to 1994. With the publicly traded American Medical Response, a medical transportation company, Mr. Bingaman led AMRs highest performing business unit from $36 million to $125 million in revenue in just 4 years as regional CEO and Senior Corporate Vice President from 1994 to 2008. Promoted to Senior Vice President for National Operations from 1998 to 2002, he led a $1.3 Billion mission critical medical services business with operations in 44 states, 250 sites and 22,000 employees then conducted 4 years of successful turnarounds and roll outs of major technology and business process improvement initiatives producing a net profit swing of approximately $37 million. He also met and exceeded all financial targets in nearly 20 consecutive quarters through organic and acquisition growth. Mr. Bingaman secured $1.05 billion career medical business development revenue from multi-year high performance service contracts [SLAs] of $1-$25 million in commercial and government sectors. Mr. Bingaman holds a BA 2008 and MBA 2010 from The Corllins University and is graduate of the Valley Medical Center School of Medicine’s Paramedicine Program 1976. Most recently he has served an executive position at the positions listed below.

Recent Experience:

2010 2014: President: Aspen Ventures, Venture Firm

2014 2015: Chief Operating Officer: East Coast Ambulance LLC., Healthcare Industry

2015 2015: President: Millennium Healthcare, Inc, Healthcare Industry

2015 April 2016: Chief Operating Officer, EVP, Secretary: Ihealthcare, Inc. (Florida Corporation)

Corporate Governance

The Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations. The Company has not formally adopted a written code of business conduct and ethics that governs the Company’s employees, officers and Directors as the Company is not required to do so.

In lieu of an Audit Committee, the Company’s Board of Directors, is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope, results and effectiveness of the annual audit of the Company's financial statements and other services provided by the Company’s independent public accountants. The Board of Directors, the Chief Executive Officer and the Chief Financial Officer of the Company review the Company's internal accounting controls, practices and policies.

Committees of the Board

Our Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does our Company have a written nominating, compensation or audit committee charter. Our Officers and Directors believe that it is not necessary to have such committees, at this time, because the Directors can adequately perform the functions of such committees.

Audit Committee Financial Expert

Our Board of Directors has determined that we do not have a board member that qualifies as an “audit committee financial expert” as defined in Item 407(D)(5) of Regulation S-K, nor do we have a Board member that qualifies as “independent” as the term is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange Act of 1934, as amended, and as defined by Rule 4200(a)(14) of the FINRA Rules.

We believe that our Directors are capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting. The Directors of our Company does not believe that it is necessary to have an audit committee because management believes that the Board of Directors can adequately perform the functions of an audit committee. In addition, we believe that retaining an independent Director who would qualify as an "audit committee financial expert" would be overly costly and burdensome and is not warranted in our circumstances given the stage of our development and the fact that we have not generated any positive cash flows from operations to date.

Involvement in Certain Legal Proceedings

Our Officers and Directors have not been involved in or a party in any of the following events or actions during the past ten years:

1.	any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
2.	any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
3.	being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or
4.	being found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.
5.	Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;
6.	Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;
7.	Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:(i) Any Federal or State securities or commodities law or regulation; or(ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or(iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
8.	Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Independence of Directors

We are not required to have independent members of our Board of Directors, and do not anticipate having independent Directors until such time as we are required to do so.

Code of Ethics

We have adopted a formal Code of Ethics. A full copy of our Code of Ethics is attached herein as exhibit 99.1.

Shareholder Proposals

Our Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors. The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our Chief Executive Officer, Noel Mijares, at the address appearing on the first page of this Information Statement.

Section 16(a) Beneficial Ownership Reporting Compliance

Procedure for Nominating Directors

In 2016, we have not made any material changes to the procedures by which security holders may recommend nominees to our Board of Directors.

Family Relationships

There are no family relationships among our directors, executive officers or persons nominated to become executive officers or directors.

Involvement in Certain Legal Proceedings

During the past ten (10) years, none of our directors, persons nominated to become directors, executive officers, promoters or control persons was involved in any of the legal proceedings listen in Item 401 (f) of Regulation S-K.

Arrangements

There are no arrangements or understandings between an executive officer, director or nominee and any other person pursuant to which he was or is to be selected as an executive officer or director.

-12-

Table of Contents

Item 11. Executive Compensation.

The below table is in regards to our past two fiscal year ends November 30:

Name and principal position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Noel Mijares, Chief Executive Officer, President, Director	2015	0	0	0	0	0	0	0	0
Noel Mijares, Chief Executive Officer, President, Director	2016	0	0	0	0	0	0	0	0
David A Bingaman, Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Vice President, and Secretary.	2015	0	0	0	0	0	0	0	0
David A. Bingaman, Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Vice President, and Secretary.	2016	0	0	0	0	0	0	0	0

Compensation of Directors

The table above summarizes all compensation of our directors as of of two most recent fiscal year ends.

Stock Option Grants

We have not granted any stock options to our executive officers since our incorporation.

Employment Agreements

We do not have an employment or consulting agreement with any officers or Directors.

Compensation Discussion and Analysis:

Director Compensation

The Board of Directors reserves the right in the future to award the members of the Board of Directors cash or stock based consideration for their services to the Company, which awards, if granted shall be in the sole determination of the Board of Directors.

Executive Compensation Philosophy

Our Board of Directors determines the compensation given to our executive officers in their sole determination. Our Board of Directors reserves the right to pay our executive or any future executives a salary, and/or issue them shares of common stock issued in consideration for services rendered and/or to award incentive bonuses which are linked to our performance, as well as to the individual executive officer’s performance. This package may also include long-term stock based compensation to certain executives, which is intended to align the performance of our executives with our long-term business strategies. Additionally, while our Board of Directors has not granted any performance base stock options to date, the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination believes such grants would be in the best interests of the Company.

Incentive Bonus

The Board of Directors may grant incentive bonuses to our executive officer and/or future executive officers in its sole discretion, if the Board of Directors believes such bonuses are in the Company’s best interest, after analyzing our current business objectives and growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and ability of such executives.

Long-term, Stock Based Compensation

In order to attract, retain and motivate executive talent necessary to support the Company’s long-term business strategy we may award our executive and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board of Directors, which we do not currently have any immediate plans to award.

-13-

Table of Contents

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

As of November 30, 2016, the Company has 1,000,000 shares of common stock and no shares of preferred stock issued and outstanding.

*The table below is as of November 30, 2016.

Name and Address of Beneficial Owner	Shares of Common Stock Beneficially Owned	Common Stock Voting Percentage Beneficially Owned	Voting Shares Preferred Stock Are Able to Vote	Preferred Stock Voting Percentage Beneficially Owned	Total Voting Percentage Beneficially Owned (1)
Executive Officers and Directors
Noel Mijares	625,000	62.50%	0	0.0%	62.50%
David A. Bingaman	375,000	37.50%	0	0.0%	37.50%
5% Shareholders
N/A	-	-	-	-	-

Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act. Under this rule, certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire shares (for example, upon exercise of an option or warrant) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares is deemed to include the amount of shares beneficially owned by such person by reason of such acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the following table does not necessarily reflect the person’s actual voting power at any particular date.

Item 13. Certain Relationships and Related Transactions.

On January 14, 2016 Mr. Jeffrey DeNunzio, the sole shareholder of the Company transferred to Ihealthcare, Inc., a Florida Company, 20,000,000 shares of our common stock which represented all of our issued and outstanding shares at the time of transfer, in consideration of $34,900. The transfer was the result of the sale of the Company to Ihealthcare, Inc., the Florida Company.

On January 14, 2016 Ihealthcare, Inc., a Florida Company, became the controlling shareholder of Opulent Acquisition, Inc. At the time of the sale of Opulent Acquisition, Inc. Mr. Mijares owned 62.5% and Mr. Bingaman owned 37.5% of the issued and outstanding shares of Ihealthcare, Inc., the Florida Company.

On January 14, 2016, Mr. Jeffrey DeNunzio resigned as Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer and Director.

On January 14, 2016, Mr. Noel Mijares was appointed as Chairman of the Board of Directors, Chief Executive Officer, and President.

On January 14, 2016, Mr. David A. Bingaman was appointed as Chief Operating Officer, Vice President, and Secretary.

Pursuant to the Agreement and Plan of Merger (“Agreement”) dated April 22, 2016, by and between, Ihealthcare, Inc. a Florida Corporation (“Ihealthcare, Inc.-Florida”), and Opulent Acquisition, Inc., a Delaware Corporation, (“Ihealthcare, Inc.-Delaware” or the “Surviving Corporation), jointly the (“Constituent Corporations”) effective as of April 22, 2016, Ihealthcare, Inc.-Florida merged with and into Ihealthcare, Inc.-Delaware with Ihealthcare, Inc.-Delaware continuing as the Surviving Corporation.

The board of directors of the Constituent Corporations have declared the Merger Agreement advisable, fair to and in the best interests of the Constituent Corporations and have approved the Merger.

Immediately before the effective time of the Merger each share of common stock, par value $0.0001 per share of Ihealthcare-Delaware held by Ihealthcare-Florida was cancelled. Each share issued and outstanding of Ihealthcare-Florida held by the shareholders was converted into one hundred validly issued, fully paid, and nonassessable shares of common stock, par value $0.0001 per share of Ihealthcare-Delaware.

On April 22, 2016, the Company filed with the Delaware Secretary of State an amendment to the Company’s certificate of incorporation, changing its name to Ihealthcare, Inc.

On May 13, 2016 David A. Bingaman was appointed as Chief Financial Officer, Chief Accounting Officer, and Director.

On July 25, 2016 we, Ihealthcare, Inc., organized Ihealthcare Surgical, LLC, a Florida Limited Liability Company. The members of the LLC include Ihealthcare, Inc., and All in 1 Medical, LLC. Each of the aforementioned parties own 50% of the membership interests in Ihealthcare Surgical, LLC. All in 1 Medical, LLC is owned and operated by Mark Heffner, who is a non-affiliate of Ihealthcare, Inc.

As of November 30, 2016 Ihealthcare Surgical, LLC has not had any monetary transactions. Per the above the Company has applied ASC 323 for presentation and disclosure requirements. Because Ihealthcare Surgical, LLC conducted no monetary business as of November 30, 2016 there were no transactions recorded on the books for the period.

On August 19, 2016 Ihealthcare Surgical, LLC, entered into and consummated a joint venture agreement with All In 1 Medical, LLC. The purpose of the joint venture agreement is to forge a relationship that through means, which will be determined at a future date, will bring together both parties in an effort to sell, to be determined, medical products. Each party retains a 50% interest in the joint venture. Each party has also agreed to split profits and expenses equally that relate to the joint venture. The term of the joint venture agreement is through August 4, 2026. It may be renewed for an additional five year term if agreed upon by both parties. Each party of the joint venture agreement has agreed to contribute $500 for business purposes set forth in the joint venture agreement. Neither party has, as of the date of this report, contributed the $500, however both parties intend to make such contribution after a joint bank account is opened up for the purpose of the joint venture. Per the aforementioned ASC 808 does not apply since the entity, is setup as a wholly owned subsidiary and ASC 323 would not apply since there is no consideration paid as of the year ended November 30, 2016.

On October 3, 2016 Ihealthcare Surgical, LLC entered into and consummated an agreement with Precision Spine, Inc., “Precision,” to act as Precision’s sales agent in regards to the sale of spinal implants and other medical products that are manufactured for or by Precision. Ihealthcare, Inc. is to receive a 40% commission on the sale of spinal implants for the fourth quarter of 2016 and effective January of 2017, 35%, +5% each quarter if Ihealthcare is able to generate sales of $300,000 or more in a quarterly period. For “Biologic” products as they are categorized in the agreement, Ihealthcare will receive a to be decided upon commission that is agreed upon by both parties at a later date. Regarding disposable single use instruments, Ihealthcare, Inc. will receive a 20% commission for any sales generated on Precision’s behalf. On December 6, 2016 ihealthcare Surgical, LLC and Precision Spine, Inc. mutually agreed to the termination of the agreement entered into on October 3, 2016. There were no revenues generated under this agreement.

On November 25, 2016 iHealthcare Surgical, LLC entered into an agreement with S1 Spine. Under the terms of the agreement S1 Spine has appointed iHealthcare Surgical, LLC to act as its sales agent to solicit orders for the products of S1 Spine. Sales are to be attempted, by iHealthcare Surgical LLC in Florida, Georgia, Nevada and New Mexico. In exchange for operating as the sales agent for S1 Spine, iHealtcahre Surgical shall receive a commission based upon the net invoice price of products offered for sale. There were no revenues generated under this agreement.

During the year ending November 30, 2016, the Company borrowed $19,045 from its CEO to pay for expenses on behalf of the company in the current year and $7,500 of these payments were posted as a reduction to subscription receivable. As of November 30, 2016, the Company was indebted to the Chief Executive Officer of the Company in the amount of $11,545, which is noninterest bearing, unsecured, and due on demand.

Our office space is located at 3901 NW 28th Street, 2nd Floor, Miami, FL 33142 . This space is provided to the Company rent free by Noel Mijares, who leases the office space on his personal behalf.

Review, Approval and Ratification of Related Party Transactions

Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification of transactions, such as those described above, with our executive officer(s), Directors and significant stockholders. We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional Directors, so that such transactions will be subject to the review, approval or ratification of our Board of Directors, or an appropriate committee thereof. On a moving forward basis, our Directors will continue to approve any related party transaction.

Item 14. Principal Accounting Fees and Services.

Below is the aggregate amount of fees billed for professional services rendered by our principal accountants with respect to our last two fiscal years.

		2016	2015
Audit fees	MaloneBailey, LLP	$12,920	$3,750
Audit-related fees		4,890	-
Tax fees		-	-
All other fees		-	-

Total		$17,810	$3,750

Board of Directors Pre-Approval Process, Policies and Procedures

Our principal auditors have performed their audit procedures in accordance with pre-approved policies and procedures established by our officers and directors. Our principal auditors have informed our sole director of the scope and nature of each service provided. With respect to the provisions of services other than audit, review, or attest services, our principal accountants brought such services to the attention of our officers and director prior to commencing such services.

-14-

Table of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Financial Statements

1. Financial statements for our company are listed in the index under Item 8 of this document

2. All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b) Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description
3.1		Restated Certificate of Incorporation (1)

3.2		By-laws (1)

10.1		Merger Agreement (1)

10.2		Distribution Agreement with ILS (1) *

31		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-K (2)

32		Certification of the Company’s Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2)

99.1		Code of Ethics (2)

101.INS		XBRL Instance Document (3)

101.SCH		XBRL Taxonomy Extension Schema (3)

101.CAL		XBRL Taxonomy Extension Calculation Linkbase (3)

101.DEF		XBRL Taxonomy Extension Definition Linkbase (3)

101.LAB		XBRL Taxonomy Extension Label Linkbase (3)

101.PRE		XBRL Taxonomy Extension Presentation Linkbase (3)

(1) Filed as an exhibit to the Form 8-K filed with the SEC on September 8, 2016.

(2) Filed herewith.

(3) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Transition Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

(*) This indicates that we have filed for confidential treatment of this exhibit and a full un-redacted copy of this exhibit has been provided to the SEC.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

iHealthcare, Inc.

(Registrant)

By: /s/ Noel Mijares

Noel Mijares, Chief Executive Officer

Dated: March 14, 2017

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ Noel Mijares

Noel Mijares, Chief Executive Officer

Dated: March 14, 2017

By: /s/ David A. Bingaman

David A. Bingaman, Chief Financial Officer

Dated: March 14, 2017

-15-

Filing Compare · iHealthcare, Inc.